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“Nous avons trois moyens principaux : l’observation de la nature, la réflexion et 
l’expérience. L’observation recueille les faits ; la réflexion les combine ; l’expérience 
vérifie le résultat de la combinaison. Il faut que l’observation de la nature soit assidue, 
que la réflexion soit profonde, et que l’expérience soit exacte.  
On voit rarement ces moyens réunis” 
 
 
Denis Diderot 
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Resumo 
 
Introdução: Atualmente o cancro é a segunda doença que mais mata nos países 
ocidentais, sendo o cancro colo-rectal (CRC) um dos mais incidentes e mortais, 
excluindo o cancro da pele melanoma. De acordo com o modelo de progressão proposto 
por Fearon e Vogelstein, CRC resulta da acumulação de alterações genéticas e 
epigenéticas, resultando na transformação de epitélio glandular normal em adenoma, o 
que pode posteriormente propiciar a progressão para adenocarcinoma. As principais 
vias moleculares de carcinogénese associadas ao CRC são a instabilidade 
cromossómica (CIN), instabilidade microssatélite (MSI) e fenótipo de metilação de ilha 
CpG (CIMP).  Ilhas CpG são regiões no genoma cuja percentagem de dinucleótidos 
CpG é superior ao que seria de esperar considerando uma distribuição aleatória de 
nucleótidos. Considerando o genoma humano, tem sido reportado que 
aproximadamente metade de todos os genes que codificam proteínas possuem uma 
ilha CpG na sua região promotora, a metilação nestas ilhas CpG pode induzir o 
silenciamento transcricional. Por esta razão, biomarcadores baseados na metilação de 
DNA podem ser utilizados tanto no diagnostico como no prognóstico de CRC. E apesar 
de já alguns testes baseados neste principio estarem a ser comercializados, a falta de 
consenso quanto à sua especificidade e/ou sensibilidade têm levantado dúvidas quanto 
á sua eficácia. Por este motivo, mais investigação é necessária no sentido de encontrar 
um bom teste de diagnóstico. A metilação em alguns genes tem sido reportada como 
um indicador global de cancro, como é o caso do Adenomatous polyposis coli (APC) e 
Ras association domain family 1 - isoform A (RASSF1A), presente em vários tipos de 
cancro, já a metilação em outros genes tem sido descrita como sendo bastante 
especifica para CRC, como são o caso do MutL homolog 1 (MLH1), O-6-methylguanine-
DNA methyltransferase (MGMT), septin 9 (SEPT9) e insulin-like growth factor 2 (IGF2). 
Assim um painel de biomarcadores constituído por alguns destes genes poderá 
apresentar uma boa especificidade e sensibilidade e desta forma ter potencial uso no 
diagnóstico e prognóstico do CRC. 
 
Objetivo: Desenvolver um método não invasivo para detetar tumores primários 
de CRC baseado na avaliação nos níveis de metilação da região promotora de genes 
selecionados.  
 
Métodos: Os níveis de metilação para os genes selecionados foi determinado 
para um total de 214 casos de tecido primário tumoral (CRC) e 50 casos de mucosa 
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normal (CRN). Todas as amostras foram obtidas a partir de tecido parafinado do IPO-
Porto. Tanto as áreas tumorais como as de tecido normal, dependendo de se tratar de 
CRC ou CRN, foram dissecadas manualmente, seguindo-se a extração de DNA e 
tratamento bissulfito. Os níveis de metilação foram determinados com recurso a PCR 
quantitativo especifico de metilação (qMSP) usando SYBR Green I para a deteção do 
amplicon e ACTβ para a normalização.  
 
Resultados: Os níveis de metilação no SEPT9, RASSF1A, MGMT e APC foram 
superiores no tecido tumoral, enquanto que no IGF2, foram menores, comparativamente 
com o observado para o tecido normal. Separando a análise pela localização do tecido, 
só o SEPT9, MGMT e RASSF1A para o colon e o SEPT9, MGMT e APC para o recto, 
apresentaram níveis de metilação significativamente superiores no tecido tumoral 
quando comparados com tecido normal. Para os tumores do recto, pacientes que 
fizeram tratamento neoadjuvante apresentavam níveis de metilação significativamente 
inferiores no SEPT9 (P=0,002) e MGMT (P=0,012). Tanto para tumores no colon como 
no recto, foram observados níveis de metilação superiores em mulheres no MGMT 
(P=0,048 e P=0.049, respetivamente) e MLH1 (P=0,007 e P=0,010, respetivamente) 
comparativamente com os níveis observados em homens. De forma geral, os genes 
selecionados foram capazes de detetar CRC em tumores independentemente da via 
molecular seguida, MSI ou CIN. Os genes com a melhor performance em termos de 
diagnostico foram o SEPT9 com 85,5% de sensibilidade e 94,0% de especificidade, logo 
seguido pelo MGMT, com 77,2% de sensibilidade e 84,0% de especificidade. Já o painel 
com a melhor performance é constituído por SEPT9/MGMT/RAASF1A com 96.6% de 
sensibilidade, 74.0% de especificidade, PPV(valor preditivo positivo)=91.5% e 
NPV(valor preditivo negativo)=72.5%. A taxa positiva de deteção usada para avaliar a 
performance do painel selecionado entre as duas possíveis localizações do tumor e 
estadiamento, mostrou que o painel consegue detetar tumor em ambas as localizações 
e todos os estadios da doença com um valor sempre acima de 90%. Para além disso 
foi observado valor prognóstico para dois dos genes, sendo que a hipermetilação do 
SEPT9 e MLH1 mostraram estar significativamente associadas com um melhor 
prognóstico. 
 
Conclusão: O painel com melhor acuidade diagnóstica foi o 
SEPT9/MGMT/RASSF1A, demostrando melhor sensibilidade, PPV e NPV que o SEPT9 
sozinho. O MGMT contribui com um enorme aumento na sensibilidade e NPV e o 
RASSF1A mantém esta tendência de aumento. Os resultados deste estudo suportam a 
FCUP 
 
VII 
 
ideia de que o MGMT é um excelente biomarcador para ser utilizado em conjunto com 
o SEPT9 em ensaios que visem o diagnóstico de CRC.  
 
Palavras-chave: Cancro Colo-rectal; Metilação de DNA; Biomarcadores; 
Diagnostico; Prognostico;   
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Abstract 
 
Background: Currently, cancer is the second most deadly disease in western 
countries and colorectal cancer (CRC) is one of the most incident and deadly, excluding 
non-melanoma skin cancer. According with commonly accepted model proposed by 
Fearon and Vogelstein, CRC results from the accumulation of both acquired genetic and 
epigenetic changes, which results in transformation of normal glandular epithelium into 
adenoma, that can progress to adenocarcinoma. According with molecular alterations, 
colorectal tumors are classified into three main pathways: chromosomal instability (CIN), 
microsatellite instability (MSI) and CpG island methylation phenotype (CIMP). CpG 
islands are regions in the genome where the percentage of the CpG dinucleotides is 
higher than would be expected, based upon a random distribution of nucleotides. It has 
been described that approximately half of all encoding-protein genes in the human 
genome contain a CpG island in their promoter region. As a consequence of their 
location in the promoter, methylation of CpG island may induce transcriptional silencing. 
Therefore, DNA methylation biomarkers might be used in diagnosis and prognosis of 
CRC. Although there are already DNA-methylation based tests being commercialized, 
their lack of specificity and/or sensitivity requires additional investigation. Previous 
reports have demonstrated potential usefulness of several genes, not only to detect 
cancer globally, such as Adenomatous polyposis coli (APC) and Ras association domain 
family 1 - isoform A (RASSF1A), and specifically to detect CRC such as MutL homolog 
1 (MLH1), O-6-methylguanine-DNA methyltransferase (MGMT), septin 9 (SEPT9) and 
insulin-like growth factor 2 (IGF2). Therefore, a panel of these genes might result in a 
robust DNA-methylation based test with good sensitivity and specificity leading to a 
potential use in diagnosis and prognosis of CRC.   
 
Aims: To develop a non-invasive method to detect primary recurrent colorectal 
tumors based on the evaluation of promoter methylation of a selected panel of genes. 
 
Methods: The methylation of CpG islands in the selected genes were analyzed 
in 214 cases of CRC and 50 normal controls (CRN). All the samples were obtained from 
paraffin-embedded tissues blocks from the IPO-Porto. The tumor and normal areas were 
dissected manually followed by DNA extraction and bisulfite conversion. The methylation 
status was determined by quantitative methylation specific PCR (qMSP) using SYBR 
Green I. The results were normalized using ACTβ.  
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Results: Methylation levels on SEPT9, RASSF1A, MGMT and APC were higher 
in tumor tissue, while in IGF2, higher methylation levels were found in normal tissue. 
When the tissue was separated by location, only SEPT9, MGMT and RASSF1A for 
colon, and SEPT9, MGMT and APC for rectum, showed significantly higher methylation 
for CRC tissues when compared to CRN. It was also observed, only for rectum, lower 
methylation levels in CRC tissues that went through neoadjuvant treatment for both 
SEPT9 (P=0.002) and MGMT (P=0.012). Higher methylation levels were found in 
women, in both colon and rectum, for MGMT (P=0.048 and P=0.049, respectively) and 
MLH1 (P=0.007 and P=0.010, respectively). In a generally way, selected genes were 
able to detect CRC in tumors either following MSI or CIN pathways. The genes with the 
best diagnosis performance were SEPT9 with 85.5% sensitivity and 94.0% specificity, 
followed by MGMT with 77.2% sensitivity and 84.0% specificity. While the panel with the 
best performance was SEPT9/MGMT/RASSF1A with 96.6% sensitivity, 74.0% 
specificity, PPV=91.5% and NPV=72.5%. The positive detection rate used to evaluate 
the panel performance among the tumor location and stage, showed that the selected 
panel was able to detect tumors in both locations and all tumor stages (positive detection 
rates above 90%). Furthermore, some genes had prognosis value, hypermethylation in 
SEPT9 and MLH1 was associated with better prognosis. 
 
Conclusion: The panel with the best diagnosis performance is 
SEPT9/MGMT/RASSF1A with better sensitivity, PPV and NPV than SEPT9 alone. 
MGMT contributes with a huge increase in sensitivity and NPV, while RASSF1A, as a 
global cancer marker, contributes as well to the increase of panel sensitivity and NPV. 
Our data supports MGMT as a great biomarker to be used along with SEPT9 in a DNA 
methylation assay for CRC detection.  
 
Keywords: Colorectal cancer; Gene promoter methylation; Biomarkers; 
Diagnosis; Prognosis; 
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Introduction 
 
Cancer 
 
Normal cells evolve to a neoplastic state by acquiring a succession of biological 
properties, also known by “hallmarks of cancer” (Figure 1). At the present, a total of ten 
hallmarks are acknowledged, including: sustaining proliferative signaling, cell death-
resistance, growth suppressors evasion, immune destruction avoidance, angiogenesis, 
replicative immortality, tumor promoting inflammation, genome instability and mutation, 
deregulated cellular energetics and invasion and metastatic capacities [1].  
 
 
Figure 1 – Scheme pointing out some of key traits involve in cancer progression. This represents a typical 
epithelial cancer, such as those that typically arise in the lung, colon, breast, or prostate [2]. 
 
 
Colorectal cancer: Incidence, risk factors and treatment  
 
Incidence 
 
Cancer is, currently, the second most deadly disease [3]. Colorectal cancer 
(CRC) is one of the most incident and deadly type of cancer, excluding non-melanoma 
skin cancer (Figure 2). CRC is the third most incident and the fourth most deadly type of 
cancer worldwide [3]. Being the third most common cancer in men and second in women. 
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Regarding mortality, it is ranked in third position for females and in the fourth in males 
[4]. 
 
 
Figure 2 – World’s incidence of different types of cancer for both sexes, all ages. Estimated number of cancer 
cases in 2012. (Adapted from [4]) 
 
In Europe, in 2012, there were estimated 3,45 million new cases of cancer 
(excluding non-melanoma skin cancer) and 1,75 million deaths due to cancer [5]. CRC 
was the second most incident and deadly type of cancer. Whereas, for woman, CRC 
was the second most incident and deadly, for man was the third most incident and 
second most deadly [5] (Figure 3).  
Considering our country, both in man and woman, CRC is the second most 
incident and deadly type of cancer following the European trend [5] (Figure 3). 
 
 
Figure 3 – Incidence and mortality for the ten most incident types of cancer in Europe (A) and Portugal (B) by 
gender [5]. 
 
Types of CRC 
 
The majority of colorectal cancers are adenocarcinomas. But this is not the only 
primary type of cancer found in this location. Besides adenocarcinoma, other types of 
cancer are found, specifically, the gastrointestinal stromal tumor, the carcinoid tumor, the 
FCUP 
DNA Methylation for detection of primary colorectal tumors 
3 
 
squamous cell cancer of the anus, and the lymphoma. The first two types are, 
respectively, developed from interstitial cells of Cajal and gastrointestinal 
neuroendocrine cells. Regarding the squamous cell cancer of the anus, it is associated 
with infection by human papilloma virus. [6].  
Considering the histologic types of CRC, they are categorized according to the 
classification proposed by the World Health Organization (WHO), recommended by the 
College of American pathologists (CAP). The types included in this classification are: 
adenocarcinoma; carcinoma no other specification (NOS); Adenocarcinoma in situ; 
cribriform comedo-type, micropapillary and serrated adenocarcinomas; medullary, 
mucinous, signet ring cell, squamous cell (epidermoid), spindle cell, and 
adenosquamous carcinoma; neuroendocrine carcinoma (NEC), large NEC and small 
NEC; undifferentiated carcinoma; and mixed adenoneuroendocrine carcinoma [7, 8]. 
Some examples are displayed on Figure 4 considering normal colon (A) as reference. 
 
 
Figure 4 – Mucosa histology. A, Normal colon (from patient CRC176). B, Adenocarcinoma with neoplastic cells 
displaying mucus production (from patient CRC267). C, Mucus with neoplastic cells (from patient CRC267). D, 
Adenocarcinoma displaying a cribriform architecture (from patient CRC383). 
 
At a superficial level CRC can be classified according to its origin into sporadic 
or hereditary. Sporadic CRC is a somatic genetic disease without known contribution 
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from germline causes, significant family history of cancer or inflammatory bowel disease. 
In other hand, hereditary CRC is due to germline alterations [9]. 
 
Risk Factors 
 
The risk factors for CRC can be divided into two categories: genetic and 
environmental. The genetic risks are due to personal and family history in which genetic 
characteristics are implicated. While the environmental risks are related with the diet, 
sedentary lifestyle, obesity, smoking and alcohol [6, 8]. All these risk factors might 
interact with each other, leading to initiation and development of the disease [10].   
Considering the family history, first-degree relatives with CRC and inherited 
syndromes are the main appointed risk factors. There are several syndromes associated 
with CRC, the two most common are hereditary nonpolyposis colorectal cancer 
(HNPCC), also known by Lynch syndrome or cancer family syndrome, and familial 
adenomatous polyposis (FAP). The other syndromes caused by germline mutations are 
MYH-associated polyposis (MAP), Cowden syndrome, Juvenile polyposis, Peutz-
Jeghers syndrome and Bannayan-Ruvalcaba-Riley syndrome [10, 11]. However, the 
genetically inherited syndromes of CRC are very rare (3-5%). Moreover, high incidence 
of CRC can be observed in a given family without a genetically inherited syndrome been 
involved [6]. Persons who have adenoma in first-degree relatives have an increased risk 
of colorectal cancer, with a relative risk (RR) of 4.38 (95% confidence interval (CI), 2.25-
8.43) when compare to persons who don’t have this personal history [12]. 
Regarding the personal history, the risks are age higher than 40 years old, a 
history of previous CRC or inflammatory bowel disease [13], male gender and diabetes 
mellitus [8, 11]. Indeed, it has been described that men have a higher risk of developing 
both colon (OR=1.4) and rectal cancer (OR=1.7) when compared with women [6, 14]. 
Diabetes was associated with an increased risk of CRC, compared with no diabetes, 
RR=1.26 (95% CI, 1.20-1.31), considering a meta-analysis of 24 studies [15].  
Risk factors associated with the diet are still controversial. It has been generally 
accepted that a diet high in fat, red meat and processed meat increases the chances of 
developing CRC [16]. Considering a dose-response meta-analyses, red and processed 
meat intake (for 100g/day increase) was significantly related to an increased risk of 
colorectal, RR=1.14 (95% CI, 1.04-1.24), colon with a RR of 1.25 (95% CI, 1.10-1.43), 
and rectal cancer with a RR=1.31 (95% CI, 1.13-1.52) [17]. However, the effect of fiber 
intake in CRC has been extensively debated. Some studies showed that the high intake 
of fiber have a protective effect on CRC, while other studies fail to reach the same 
conclusions [6].    
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As mentioned earlier, smoking increases the risk of CRC, considering twenty-six 
studies pooled together, in a meta-analysis, smoking has a RR of 1.18 (95% CI, 1.11-
1.25) comparing ever smokers to never smokers [18].  
The alcohol intake increases the risk of CRC, comparing with non-drinkers, the 
pooled multivariable RR were 1.16 (95% CI, 0.99-1.36) for persons who consumed 
between 30-45 g per day and 1.41 (95% CI, 1.16-1.72) for those who consumed more 
than 45 g per day [19]. 
Considering the increased risk of CRC with obesity, a 5 unit increase in body 
mass index (BMI) was related with an increased colon cancer risk in man, RR=1.30 (95% 
CI, 1.25-1.35) and woman, RR=1.12 (95% CI, 1.07-1.18). Despite this, in rectal cancer, 
BMI was associated with an increased risk in man, RR=1.12 (95% CI, 1.09-1.18), but 
this association was not found in woman, RR=1.03 (95% CI, 0.99-1.08) [20]. Herein, the 
relation between obesity and colon and rectal cancer risk varies by gender and cancer 
site [20]. 
 
Diagnosis 
 
Several aspects have to be taken into account for diagnosis. More advanced 
stages of CRC have a few symptoms associated while a yearly-stage for not having 
those can go unnoticed for a while. The main symptoms associated with CRC are rectal 
bleeding, weight loss, abdominal pain, diarrhea, constipation, abnormal rectal 
examination, abdominal tenderness, haemoglobin <10.0 g/dL, positive faecal occult 
blood and blood glucose >10 mmol/L [21]. 
Screening is made in the general population in order to detect a pre-cancer 
condition or a very early-stage malignancy before it being symptomatic [22]. The most 
frequent examinations used are colonoscopy, guaiac-based faecal occult blood test, 
imaging to help identify metastatic disease, where it can be included computed 
tomography (CT), magnetic resonance imaging (MRI), x-ray and positron emission 
tomography (PET), and finally, endorectal ultrasound [23]. For a definitive diagnosis, a 
tumor biopsy is performed in order to obtain a histological confirmation. 
 
Staging 
 
After the CRC diagnosis, clinical examination, laboratory tests and instrumental 
search for metastasis should be performed in order allow a complete staging.  
The disease stage is described according to the TNM system, following the 
guidelines of American Joint Committee on Cancer (AJCC)/ Union for International 
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Cancer Control (UICC) as shown in Table 1. In TNM, T stands for Primary Tumor, N for 
Regional Lymph Nodes, and M for Distant Metastasis. To evaluate the microscopic 
invasion (T), it is considered the histologic layers displayed on Figure 5. Further, TNM 
stage can be written with the prefix letters c, p, y or r,  where the c stands for a clinical 
classification, p for the pathologic one, y for those cancers that were classified after 
neoadjuvant pretreatment and the r is used for those cancers that had recurred after a 
disease-free interval [7].   
 
Table 1 – TNM classification of colorectal cancer according to AJCC/UICC guidelines (Adapted from [7]). 
T - Primary Tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades through the muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in one regional lymph nodes 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumor deposit(s) in the serosa, mesentery, or nonperitoneal tissues without regional 
nodal metastasis 
N2 Metastasis in four or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in seven or more regional lymph nodes 
M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site 
M1b Metastases in more than one organ/site or the peritoneum 
 
Each case can be staged for several times, normally the first time is at diagnosis. 
The first staging is very important since it will define the first line treatment. Then, it can 
be stage after any treatment, chemotherapy/radiotherapy or even surgery. Hence, it is 
possible to assess the disease progression, allowing the necessary treatment 
adjustments upon the new TNM classification [7].  
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Figure 5 – Tissue layers of colon (Adapted from [7]). 
 
The anatomic staging and histology grade should be determined as well (Table 
2). Histologic grade can be classified into low grade (Well/Moderately differentiated) and 
high grade (poorly differentiated and undifferentiated).  
 
Table 2 – Anatomic Stage/Prognostic Grouping with the correspondent TNM classification (at the left side). And 
Histologic grade (at the right side) (Adapted from [11]) 
Stage TNM Correspondence   Histologic Grade 
I T1-2, N0, M0   GX Grade cannot be assessed 
IIA T3, N0, M0   G1 Well differentiated 
IIB T4a, N0, M0   G2 Moderately differentiated 
IIC T4b, N0, M0   G3 Poorly differentiated 
IIIA T1-2, N1, M0   G4 Undifferentiated 
IIIB T3-4, N1, M0     
IIIC T1-4, N2, M0     
IVA T1-4, N1-2, M1a     
IVB T1-4, N1-2, M1b     
 
In order to have a complete staging, the tumor location is needed. In Figure 6 the 
anatomic division of the colon, from the appendix until the anus is displayed. 
The AJCC/UICC classification system is most commonly considered international 
standard for CRC staging system. However, others like Dukes and the Modified Astler-
Coller classification (MAC) can be alternatively used for staging [8]. 
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Figure 6 – Anatomic subsites from appendix to anus. 
 
After primary surgical resection, the postoperative residual disease status of the 
patient should be evaluated. This status reflects the efficacy of primary treatment and is 
categorized by the R classification system (Table 3). This classification has a stage-
independent prognostic value, where, at any stage of disease, R1 and R2 are adverse 
prognostic factors when compared to R0. The R0 code refers not only to the absence of 
primary tumor but also to the absence of tumor dissemination, namely the absence of 
distant metastasis [7, 8].  
 
Table 3 – R classification system. (Adapted from [7]) 
RX Presence of residual tumor cannot be assessed 
R0 Complete tumor resection with all margins histologically negative 
R1 Incomplete tumor resection with microscopic residual tumor 
R2 Incomplete tumor resection with macroscopic residual tumor 
 
Besides the postoperative residual disease status, when the patient is submitted 
to preoperative adjuvant (neoadjuvant) treatment, the tumor regression grade should 
also be appraised. This evaluation is made according to the CAP guidelines, consisting 
in a four-point tumor regression grade as shown in Table 4 [7].  
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Table 4 – Tumor regression grade (Adapted from [7]). 
Tumor regression grade Description 
0 (Complete response) No viable cancer cells 
1 (Moderate response) Single cells or small groups of cancer cells 
2 (Minimal response) Residual cancer outgrown by fibrosis 
3 (Poor response) Minimal or no tumor kill; extensive residual cancer 
 
Treatments 
 
An adequate staging will guide the adequate treatment. Depending on the tumor 
location, rectum or colon, and time of detection/diagnosis, in addition to other factors, 
the therapy approach will be different. The treatment selection is a very complex process 
that will depends on multiple factors. Current treatment guidelines, are proposed by 
European Society for Medical Oncology (ESMO) and National Comprehensive Cancer 
Network (NCCN), which time to time are reviewed in the light of new knowledge [22, 24-
28]. 
According to ESMO, the treatment should be risk-adapted. Briefly, in rectal 
cancer, for the earliest and most favorable cases, a surgery involving the tumor resection 
should be enough, if the margins are tumor free (R0). When surgery is contraindicated, 
a treatment based on chemo-radiotherapy, in which local radiotherapy used alone or 
combined with neoadjuvant chemotherapy is more suitable. For intermediate cases 
preoperative radiotherapy, followed by local tumor resection is suggested. Lastly, for the 
locally advanced tumors, which are mostly not resectable, the first treatment is chemo-
radiotherapy followed by radial surgery. In some specific situations, like stage III patients 
(and “high-risk” stage II) it is given adjuvant chemotherapy as a postoperative treatment 
[26].  
In colon cancer, stage I patients are treated with surgical resection and 
anastomosis, normally no adjuvant chemotherapy is needed. For stage II patients, the 
first treatment recommended is surgical resection and anastomosis, followed by adjuvant 
therapy for high-risk patients. Stage III patients besides the surgical resection and 
anastomosis, are treated with adjuvant chemotherapy [22]. 
Both in metastatic colon and rectal cancer, the first-line of treatment is systemic. 
The chemotherapy will have a curative intention if the metastasis is potentially 
resectable, otherwise, it will be palliative [28].  
There are several different regimens of chemotherapy and subsequent different 
combinations. The regimens could be composed by only one drug (monotherapy) or 
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combined. The drugs normally used are leucovorin (LV) (also known as folinic acid, 
Isovorin or Levofolinate), 5-fluorouracil (5-FU), Oxaliplatin (Eloxatin), Irinotecan 
(Camptosar), and Capecitabine. The most commonly used combined regimens are 
FOLFOX, FOLFORI, XELOX (also known by CAPOX), XELIRI and FLOX (also known 
by de Gramont) (Table 5). Additionally, other combinations may exist and there are 
several new drugs being tested in clinical trials [24, 25].  
 
Table 5 – Most common regimens used in chemotherapy, name and composition. 
Regimens Composition 
FOLFOX 5-FU, LV and Oxaliplatin 
FOLFORI 5-FU, LV and Irinotecan 
XELOX Oxaliplatin and Capecitabine 
XELIRI Irinotecan and Capecitabine 
FLOX 5-FU and LV 
 
Moreover, chemotherapy may be combined with biologic agents. Biologic agents 
are drugs with a very local specific action, normally a component of a signaling pathway. 
The most well-known biologic agents currently been used are Bevacizumab, Cetuximab 
and Panitumumab. Bevacizumab is an antiangiogenic monoclonal antibody directed 
against all isoforms of vascular endothelial growth factor-A (VEGF-A), thus disrupting 
their interaction with vascular endothelial growth factor receptor-2 (VEGFR-2). 
Cetuximab and Panitumumab are very similar monoclonal antibodies that specifically 
target the extracellular domain of Epidermal growth factor receptor (EGFR), preventing 
a ligand-induced activation, promoting receptor internalization and degradation [8].  
 
Follow-up 
 
During cancer treatment or after completing, follow-up is a standard practice. It 
consists in periodic consultations in order to prevent recurrence and new cancer, assess 
medical and psychological late effects, and lastly promote a healthy lifestyle [22]. The 
tests used for patient’s follow-up are mostly, the same ones mentioned for diagnosis. In 
addition, serum marker carcinoembryonic antigen (CEA) testing might be used. The CEA 
is also assessed for response evaluation to adjuvant chemotherapy treatment [28]. 
Briefly, the tests commonly used in follow-up are CEA testing, full colonoscopy and CT 
scan of the thorax with abdomen and pelvis. Other tests can be performed in order to 
obtain supplementary information. The frequency of follow-up exams will depend on the 
risk associated to each patient and on the type of test that will be performed [8]. 
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Genetic and epigenetic of colorectal cancer  
 
Genetic and CRC 
 
The genetic alterations in CRC are well characterized, they involve changes in 
the deoxyribonucleic acid (DNA) sequence altering the gene product by changing the 
amino acid sequence of protein or by altering the quantity of protein produced [29]. 
Depending on the original gene function, the outcome will be different. In some specific 
tumor suppressor genes, the defects can involve loss-of-function while in certain 
oncogenes, it will involve the gain-of-function [9]. Besides the alterations observed in 
oncogenes and tumor suppressor genes, alterations in genes regulating transcription 
and translation, as well as in genes responsible for DNA repair, may occur as well [2]. 
The genetic alterations include copy-number alterations, point mutations, deletions, and 
translocations, being most of them immaterial to neoplasia [30]. Nevertheless, some of 
these somatic defects might confer a selective growth advantage to the pre-neoplastic 
cell and this way, they would be “driver” events leading to malignancy. It has been 
identified, in the human genome, about 138 driver genes, being 74 tumor suppressor 
genes and 64 oncogenes. Although, a sporadic CRC might only contain 2-8 driver gene 
alterations [9, 30]. 
As mentioned before, a small portion (3-5%) of CRC are hereditary, on Table 6 
are described the target genes mutated in some of those inherited disorders [10].  
 In addition to mutations associated with inherited conditions, there are others 
that have been described to play an important role as well. These mutations, beyond 
being relevant in terms of prognosis, are also, very informative in terms of therapy 
response [23]. For this reason, some of them are currently used in clinic as predictive 
markers. The result of this mutational analysis will define the best treatment scheme. 
Specifically, mutations at codons 12 and 13 of KRAS and at V600E (Valine 600 to 
glutamic acid) of BRAF are indicative of resistance to anti-EGFR monoclonal antibody 
therapy. Namely, KRAS mutations reduce GTPase activity, leading to constitutive 
activation of downstream pathway, whereas V600E leads to constitutive BRAF 
activation. Alterations in the enhancer region of Thymidylate synthase (TS), may also 
alter TS expression, thus, reducing or increasing patients’ response to fluorouracil [8, 
23]. 
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Table 6 – Some of the inherited disorders, and its variants, causing CRC [10]. 
Inherited Condition Genes Mutated 
HNPCC 
(Attenuated HNPCC, Muir-Torre syndrome, Trimbath 
syndrome, Turcot syndrome) 
Mismatch repair (MMR) genes: 
MLH1, MSH2, MSH6 and PMS2. 
FAP 
(Attenuated FAP, Crail syndrome) 
APC 
MAP 
(MYH-associated colon cancer) 
MYH 
Juvenile polyposis SMAD4, BMPR1A 
Cowden syndrome PTEN 
Bannayan-Ruvalcaba-Riley syndrome PTEN 
Peutz-Jeghers syndrome STK11 
 
Epigenetic and CRC 
 
Epigenetics involve gene expression regulation without changes in the DNA 
sequence and, consequently, are potentially reversible [29]. The understanding of 
human epigenome is much less detailed than the genome. This might be due to the fact 
that there are almost as many epigenomes as cell types, despite the slight differences 
between tissues, the fraction of changes have a huge impact in both differentiation and 
disease [31]. The epigenetic mechanisms include DNA methylation, histone post-
translational modifications, non-coding RNAs (NcRNA), and histone variants (Figure 7). 
CH Waddington was the first to introduce the concept of epigenetics in 1939, but only in 
1983 it was associated with cancer [31].  
CRC is one of the types of cancer in which, over the years, consistent patterns of 
epigenetic alterations, has been described. The most frequently described alteration is 
only present in a subgroup of CRC, and it consists in the promoter hypermethylation of 
several genes leading to their inactivation. This alteration is also known by CpG 
(Cytosine phosphate Guanine) island methylator phenotype (CIMP) [2]. Besides CIMP, 
other epigenetic alterations can be found in CRC, such as, aberrant histone modification 
changes, and microRNA (miRNA) and long noncoding RNAs (lncRNA) deregulated 
expression [32].  
CpG islands are genomic regions in which the percentage of the CpG 
dinucleotides is higher than it would be expected (based upon a random distribution of 
nucleotides). These regions are defined as 500-1000 bases in length with greater than 
50% CG (cytosine and guanine) content and ratio of observed to expected CpGs of >0,6 
[33]. Cytosine methylation is catalyzed by DNA methyltransferases (DNMTs). The 
methylation maintenance during replication is ensured by DNMT1, while de novo 
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methylation is catalyzed by DNMT3A and DNMT3B [34]. The DNA is regulated not only 
by DNMT but also by transcription factors. Several factors may contribute to aberrant 
DNA methylation. These are divided into intrinsic and extrinsic and whereas intrinsic 
factors include aging and mutations, extrinsic factors include diet, intake of mutagenic 
chemicals and smoking [34].  
 
 
Figure 7 – Scheme with the main epigenetic mechanisms that can be deregulated in cancer  [35]. 
 
There are two kinds of methylation in the human genome, the CpG and the non-
CpG methylation. The non-CpG methylation is mostly described to be present in 
embryonic stem cells (25%) and its disappearance has been reported to occur upon 
differentiation inducement. While CpG methylation is present in all kinds of cells, stem 
and differentiated [36]. 
It is well known that approximately half of all encoding-protein genes in the human 
genome contain a CpG island in their promoter region [32, 37]. As consequence of their 
location in the promoter, CpG islands methylation associate with transcriptional silencing 
[32, 38]. Therefore, the biological outcome will differ depending on where the DNA 
methylation took place. In the other side, the absence of DNA methylation does not imply 
promoter activity or increase of gene transcription. It only means that the gene becomes 
regulated by other processes [31, 39].  
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In normal cells, the CpG island promoters are normally methylation-free, only a 
few (3%) are methylated. Besides CpG island promoters, there are non-CpG island 
promoters, or CpG-poor promoters, that in normal tissues are found typically methylated. 
The relation between methylation and expression is not so clear in the last ones [31]. 
Conversely, cancer cells have a global genome hypomethylation and a gene promoter-
associated hypermethylation [39].  
Over the years several DNA methylation targets has been reported, non-CIMP 
related, both at promoter and intronic regions, that were able to distinguish between 
healthy and malignant tissues. Although not all of them were able to correctly predict 
CRC, and so, only a few of these markers were approved and advanced to clinical trials  
[34]. This comes from the fact that de novo methylation of promoter CpG islands is a 
very frequent alteration observed in cancer [31]. 
There are epigenetic driver alterations that lead to malignancy as well as 
described for genetic alterations, one example is the hypermethylation of MutL homolog 
1 (MLH1). The promoter methylation of this gene leads to its inactivation and is present 
in almost all sporadic CRC with microsatellite instability (MSI) [31].   
 
Molecular and morphological pathways in CRC  
 
CRC results from the accumulation of both acquired genetic and epigenetic 
changes, which results in transformation of normal glandular epithelium into invasive 
adenocarcinoma.  
As mentioned earlier, colorectal tumors might be classified according with various 
clinical, pathological and/or molecular features. Recently, molecular classification has 
been gaining importance because it reflects underlying mechanisms of carcinogenesis 
[40].     
The main carcinogenesis pathways implicated in CRC involve chromosomal 
instability (CIN), MSI and CIMP. Notwithstanding the importance of molecular pathways, 
the underlying the tumor morphology are also important and should not be disregarded. 
Indeed, there are two main morphology pathways to be considered, the adenoma-
carcinoma pathway and the serrated neoplasia pathway. These pathways might include 
alteration from all of the three molecular pathways. 
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Molecular pathways: CIN, MSI and CIMP 
 
There are two levels of genetic instability, a subtle one affecting only DNA 
sequences, MSI-high (MSI-H), and a grossly one, affecting portions or entire 
chromosomes, the CIN. These forms of instability are reported to be mutually exclusive, 
thus a CRC with CIN is most likely microsatellite stable (MSS) [41, 42]. 
CIN pathway was the first one to be described, although the underlying 
mechanism is still not known. This is the most common molecular pathway, affecting 
proximally 85% of sporadic CRCs. Cohorts of CRCs with CIN display several karyotype 
aberrations, which includes chromosome gains and losses, chromothripsis, 
chromosome rearrangements, focal gene amplifications and at even base substitutions 
and deletions [9]. The neoplastic transformation normally occurs through this pathway 
by copy number gains or losses of driver genes [40]. Several mechanisms potentially 
responsible for CIN have already been proposed, however neither of them were 
consistently observed [9]. 
MSI refers to altered lengths (“instability”) of short nucleotide repeat sequences 
(“microsatellites”) in tumorous DNA when compared to normal DNA. This pathway is 
considered an alternative one to CIN. MSI-H, observed in approximately 15% of sporadic 
CRCs, has been reported to be due to defects in the DNA mismatch repair (MMR) system 
[9, 40]. DNA MMR system is responsible by the in recognition and direct repair of 
nucleotide mispairs right after replication, thus ensuring two identical daughter cells 
originated by mitosis. When the system fails, DNA fidelity is lost and mutations are 
transmitted in an asymmetric manner to both daughter cells and consequently multiple 
mutations will be, eventually, accumulated in the newly formed cells. In order to assess 
the MSI status, a panel of microsatellite markers, defined by National Cancer Institute, 
need to be tested. MSI-H tumors harbour more than 30% of frameshift mutation in 
microsatellite markers [9].  
In sporadic CRC, the most common cause for defects in DNA MMR is aberrant 
bi-allelic hypermethylation of MLH1, a DNA MMR gene. MLH1 is one of the markers 
used to define CIMP, thus, there is an overlap between many CIMP tumors and MSI-H 
tumors [9]. Conversely, MSI-L has been associated with O-6-methylguanine-DNA 
methyltransferase (MGMT) methylation and its correspondent loss of expression [40, 
43]. 
As earlier mentioned, CIMP occurs in 10-40% of the patients resulting from the 
concomitant hypermethylation of selected loci depending on CIMP definition used [44]. 
CIMP is of high importance, once it affects both tumor suppressor and DNA repair genes.  
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Despite the intensive research in this field, there are no consensus guidelines on 
definition of CIMP. Moreover, there is no CIMP-gene panel robust enough to be generally 
accepted. Similarly, there is no unanimity in the marker thresholds or techniques used 
for detecting altered DNA methylation used to define this phenotype. This lack of 
consensus hampers the conclusion whether the difference in CIMP prevalence between 
studies is due to different methodologies, or in the primers’ choice and/or location of 
methylation in the markers [45]. Importantly, the biological cause of CIMP remains 
unknown. 
The categories of CIMP are an additional topic of debate. Some authors  claim 
that it should be distinguished as two categories, “CIMP” and “non-CIMP” [46], others in 
three categories, either “CIMP-high, CIMP low, CIMP-0” [47] or “CIMP1, CIMP2, CIMP-
negative” [48], and most recently, four categories, CIMP-high, CIMP-low and two clusters 
of non-CIMP depending on the frequency of TP53 mutation [38]. 
Nevertheless, it has been shown that CIMP-high is associated with proximal 
tumor location, female sex, poor differentiation, MSI, high BRAF and low TP53 mutation 
rates [44, 49-52]. Conversely, CIMP-low is associated with KRAS mutation and male sex 
[47], and CIMP-0 (CIMP-negative) is associated with wild-type BRAF/KRAS and a distal 
tumor location [40, 53].  
Currently there are two different CIMP panels being used for CIMP status 
assessment, the classical and the novel. The classical panel includes MLH1, MINT1, 
MINT2, MINT31, and p16 [54], while the novel panel is composed by CACNA1G, IGF2, 
NEUROG1, RUNX3, and SOCS1 [46]. 
 
Morphological pathways 
 
There are several forms of colorectal epithelial polyps, the adenoma and the 
serrated polyps which include hyperplastic polyps, traditional serrated adenomas and 
sessile serrated adenomas [55]. Adenomas were the first to be perceived to represent 
precursor lesions to CRC, with the first description of the classic adenoma-carcinoma 
progression model proposed by Fearon and Vogelstein [56]. Since then a lot of effort 
was made in the understanding of the biology of this malignancy resulting in successive 
revisions of the initial model. Hyperplastic polyps, in the other hand, were considered to 
have no potential for progression to malignancy, but recently was recognized that some 
polyps have a significant risk for neoplastic transformation. Thus, progressing to CRC 
through another pathway: the serrated neoplasia pathway [55]. 
The adenoma-carcinoma pathway stands that the stepwise change in 
morphology and accumulation of molecular alterations is a concomitant event. 
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Considering the morphology, it starts with the formation of a small adenomatous polyp, 
followed by progression to a larger polyp with dysplasia, which eventually will progress 
to invasive carcinoma [55, 56]. In this pathway, the first molecular abnormality to arise is 
the mutation of Adenomatous polyposis coli (APC), which is followed by the acquisition 
of mutations in KRAS and TP53 [55, 57]. This pathway responsible for sporadic CRC is 
also shared by FAP [55].  
The serrated pathway is responsible by 30% of CRC and has as end-point the 
serrated adenocarcinoma. This type of adenocarcinoma is more frequent in older 
females and in proximal colon, although being also found in the left-side colon and mostly 
in the rectum. The majority of serrated adenocarcinomas appear in association with 
traditional serrated adenomas that usually are MSS or MSI-L. The tumors arising from 
sessile serrated polyps (15-20%) are frequently MSI-H and usually are right-sided [55, 
58]. Several studies have shown that MSS or MSI-L serrated adenocarcinomas have a 
worse prognosis than non-serrated adenocarcinomas in the same conditions [59]. 
The genetic alterations observed in serrated pathway differ from the ones found 
in the adenoma-carcinoma pathway. Indeed, in the serrated pathway APC and TP53 
mutations and loss of heterozygosity are rare, whereas hypermethylation of CpG islands 
and alteration of microsatellite sequences are quite common. Right-side tumors are 
predominantly MSI-H, CIMP and BRAF mutant, while the left-side tumors are mainly 
MSS or MSI-L and are associated with KRAS mutations (Figure 8) [55]. In conclusion, 
there are two very important steps in serrated pathway: MAPK pathway activation and 
CIMP. The first occurs by either BRAF or KRAS mutation and the second can be either 
CIMP-low or CIMP-high. As mentioned before, MSI is quite frequent although is not a 
requirement of this pathway [58].  
In CRC, KRAS and BRAF activating mutations are mutually exclusive, but. 
PIK3CA mutations can coexist with mutations in any of the former genes. The KRAS 
oncogenic activation mutations at codons 12, 13, or 61 have been reported to be followed 
by APC inactivation during tumor progression [9]. 
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Figure 8 – Diagram of serrated neoplastic pathway with both morphologic and molecular steps involved, 
according to the adenoma type associated  [55]. 
 
 
Biomarkers in CRC diagnosis and prognosis  
 
A biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” by Biomarkers Definitions 
Working [60]. In addition, a biomarker should have the greatest value in early efficacy 
and safety evaluations [60]. 
DNA-based biomarkers have several advantages, being more stable than RNA 
and proteins, more practical, reliable and viable [34]. Specifically, for CRC, the search 
for biomarkers mostly based on genes promoter methylation seem to be a rather 
promising. A number of methods might be used to detect promoter methylation in tumors, 
including methylation specific PCR (MSP), real-time PCR (such as MethyLight) and 
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bisulfite pyrosequencing [61]. Remarkably, methylation might be assessed in cell free 
DNA extracted from body fluids like plasma, serum or stool [39].   
Several studies have been made to discover a methylation biomarker or a panel 
of biomarkers with high sensitivity and specificity to be used in diagnosis and prognosis 
of CRC [46-48, 62]. However, only a few biomarkers have been tested the clinical trials 
and are commercially available. A recently licensed DNA methylation assay is 
ColoVantage®, which is blood-based and evaluates septin 9 (SEPT9) methylation 
[62].The overall sensitivity of the SEPT9 methylated DNA assay was found to be 90 %, 
with 87% sensitivity for early stage CRC (stages 1 and 2) and 100% at late stage 
diagnosis (stages 3 and 4) [62]. Epi proColon® 2.0 and Abbott RealTime mS9 are other 
assays based on SEPT9 methylation that are currently used for CRC detection [63]. 
Nonetheless, the value of the SEPT9 promoter methylation has been questioned. 
Indeed, a recent study found a standardized sensitivity of only 48.2 % for CRC detection, 
although high specificity (91.5%) was confirmed [64]. 
Another assay clinically available is ColoSureTM test, which is a fecal-based 
methylation assay that assess vimentin methylation [65]. This test is recommended for 
use along with colonoscopy since its sensitivity ranged from 38-88% [65, 66].  
In addition to these DNA methylation biomarkers already being commercialized, 
there are others currently under investigation and/or clinical trials and the research for 
more effective potential biomarkers is ongoing [66]. For this reason, further studies are 
needed to find a more accurate methylation biomarker panel to be used in diagnosis and 
prognosis of CRC. 
In order to find and select genes to be analyzed, a literature review was made. In 
Appendix 1, it is explained all the steps of this search in more detail. APC and Ras 
association domain family 1 - isoform A (RASSF1A) was reported to distinguish normal 
tissues from neoplastic whereas MLH1, MGMT, SEPT9 and insulin-like growth factor 2 
(IGF2) were reported to specifically detect CRC. 
APC is a tumor suppressor gene which encodes a protein involved in Wnt 
signaling pathway inhibition, therefore having an important role in cell-cycle regulation 
and apoptosis [32, 67]. APC promoter hypermethylation has been reported in several 
types of cancer, including colorectal [68, 69]; breast [70]; lung [71]; and prostate [72]; 
among others.  
RASSF1A is also a tumor suppressor gene. The encoding protein of this gene 
acts as negative RAS effector, pro-apoptotic factor and it is involved in microtubule 
stabilization [32, 73]. Similarly to APC, this gene is reported to be hypermethylated in a 
number of cancers, including the four types mentioned for APC [73, 74].  
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MLH1 belongs to the mismatch repair system, consequently when it losses 
function or expression is lost, the cell is unable to repair DNA replication errors resulting 
in tumor initiation and progression [75, 76]. MLH1 promoter hypermethylation has been 
described in sporadic colorectal cancer [69, 76] and in endometrial cancer [77].  
IGF2 gene encodes a fetal growth factor which is normally imprinted. The IGF2 
loss of imprinting (LOI) has been associated with increased adenoma and colon cancer 
risk  indicating its role on carcinogenesis [78]. Furthermore, IGF2 LOI is correlated with 
hypomethylation at a differentially methylated region (DMR)-0 [79]. IGF2 DMR-0 
hypomethylation has been reported in colorectal cancer [78-80] and in breast cancer 
[81].  
SEPT9 belongs to a highly conserved family of septin genes coding for GTP-
Binding proteins that assemble into complexes forming filamentous structures of the 
cytoskeleton [82]. The septin proteins are important in many cellular processes, thus, 
having a major role in multiple cancers [82]. In addition of being  methylated in colorectal 
cancer [62, 63, 82], it was also reported to be overexpressed in several types of tumors: 
breast, central nervous system, endometrium, kidney, liver, lung, lymphoid, esophagus, 
ovary, pancreas, skin, soft tissue and thyroid [83].  
MGMT is a DNA repair gene which encodes a protein involved in defending cells 
against alkylating agents [84]. Promoter methylation associated with MGMT silencing 
have been reported mainly in colorectal cancer [85], but also in gliomas [86], gastric 
cancer [87], esophageal adenocarcinoma [88] and finally in oral squamous cell 
carcinoma [89].  
Thus, the aberrant methylation of these genes may result in an accurate 
biomarker panel for diagnosis and prognosis of CRC. 
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Aims 
 
In the present dissertation, the main goal was to develop a non-invasive method 
to detect primary colorectal tumors based on the evaluation of promoter methylation of 
a selected panel of genes. 
 
Specifically, the aims of this study were: 
 Assess the promoter methylation status of six selected genes (APC, 
RASSF1A, MLH1, MGMT, IGF2 and SEPT9) in a clinically and 
pathologically well characterized cohort of CRC and normal tissue 
samples.  
 Correlate the molecular results with standard clinicopathological 
parameters; 
 Establish a panel of DNA-based methylation markers for the diagnosis of 
CRC and prognosis assessment.
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Material and Methods 
 
Study Group 
 
A cohort of 214 samples of CRC and 50 samples of healthy controls (no evidence 
of CRC or other gastrointestinal cancer) were included. The CRC’s tissue samples were 
all from a primary tumor and represent the population-based CRC data in order to be a 
relatively unbiased cohort. This project was approved by the institutional ethics 
committee (CES 120/015). 
All the samples were obtained from formalin-fixed paraffin-embedded (FFPE) 
tissue blocks from the IPO-Porto hospital where the cohort of patients had undergone 
resections of primary tumors. For healthy controls, blocks from surgical margins of non-
gastrointestinal tumors with total absence of tumor tissue of any kind were used. 
Information from relevant clinicopathological parameters from all patients was collected 
from the patients’ clinical charts and put together in a data base to further analyses, like 
explained in Appendix 2. 
 
Histopathologic evaluations  
  
Haematoxylin and eosin (H&E) stained tissue sections of all the samples were 
examined under a light microscope by a pathologist to ensure that it was tumor or normal 
tissue, depending on the case. Also during the examination, the pathologist did a 
delimitation of the tumor area or normal mucosa depending on the sample. Tumors were 
classified into well, moderately or poorly differentiated. 
Immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 was performed by a 
technician for all of the CRC cases in order to evaluate any alteration in its expression 
and so understand which cases followed the MSI pathway, cases lacking expression of 
any of these proteins were classified as MSI-H, all the others were considered MSI-L or 
MSS. This evaluation was performed by a pathologist. 
 
Genomic DNA extraction 
 
DNA was extracted from FFPE tissue samples, using phenol-chloroform 
conventional method as described by Ramalho-Carvalho, Pires [86].  
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For each patient, one paraffin-embedded tissue block was considered and 12 
serials 8 µm thick unstained slides and two H&E stained slides were made by a 
technician. As described before, the H&E stained slides were examined and the area of 
interest was delimitated. The two stained slides were made with the first and last section 
from the paraffin block, all the other slides were within these two, therefore it was possible 
to assess if the tumor’s shape has change between the first and last section.  
Before the DNA extraction, the unstained slides were incubated at 55 °C for about 
30 minutes allowing the melting of some paraffin and the decrease of its amount around 
the tissue and, this way, facilitating the next step. Using a succession of reagents, the 
slides were first immerse in two xylene containers for 5 minutes in each, allowing the 
tissue deparaffination, and next, they were immerse in containers with 100%, 90%, 70% 
and 50% ethanol for 5 minutes in each by this order, allowing the tissue’s rehydration. 
Subsequently the tumor areas were delimited, by comparison with correspondent 
H&E stained slides, and macro-dissected from the tissue unstained slides. The macro-
dissected tissue was resuspended in 1000 µL of digestion buffer (Tris-HCl 0,05M, EDTA 
0,05M and Tween 20) and 25 µL of proteinase K (20 mg/mL) (NZYTech, Portugal) was 
added. Samples were incubated overnight at 55°C and after this period, if the sample 
was not totally digested, this incubation would be prolonged and more proteinase K 
would be added until complete digestion was achieved.  
Extraction was performed with phenol-chloroform (Sigma-Aldrich®, Germany; 
Merck, Germany) using Phase Lock GelTM Light 2 mL tubes (5PRIME, Germany). Briefly, 
the samples were transferred to the phase lock tubes, previously centrifuged at 12,000 
rpm for 5 minutes, and mixed with 500 µL of phenol-chloroform. After centrifugation at 
13,000 rpm for 15 minutes, the aqueous phase containing the DNA (upper phase) was 
transferred to 2 mL tubes.  
DNA precipitation was accomplished by adding to the transferred aqueous 
phase, chilled absolute ethanol (2 volumes of the original amount of this phase) (Merck 
Millipore, Germany), 7.5M ammonium acetate (1/3 volume) (Sigma-Aldrich®, Germany) 
and 2µL of glycogen (Thermo Fisher Scientific, USA). After mixing, samples were left at 
-20°C overnight. 
In the next step, DNA was washed twice with 70% ethanol using centrifugations 
at 13,000 rpm for 20 minutes. The pellets were air dried and eluted in 20µL of sterile 
distilled water (B.Braun, Melsungen, Germany). DNA was quantified and its purity 
assessed using NanoDrop ND-1000 ® (NanoDrop Technologies, DE, USA) 
spectrophotometer. All the samples were stored at -20°C until further use. 
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Sodium Bisulfite Treatment  
 
Sodium bisulfite treatment was performed in order to be able to study the 
methylation status. This method is based on a differential sensitivity to chemical 
conversion, where unmethylated cytosine residues are converted into uracil, while 5-
methylcytosines remain unchanged (Figure 9). Thus, an epigenetic event is converted 
into a genetic change allowing its analysis by PCR-based methods [90].  
This method includes several steps: starting with the DNA denaturation to 
improve the action of bisulfite; a sulphonation resulting in a cytosine sulphonate 
derivative; a hydrolytic deamination of the previous compound leading to the formation 
of a sulphonated uracil derivative; and at last, the removal of the sulphonate group by a 
subsequent alkali treatment originating the uracil residue [90].     
 
 
Figure 9 – Changes in DNA caused by bisulfite treatment and the differences between methylated CpG sites and 
unmethylated ones (Adapted from [91]). 
 
For each sample, 1000 ng of DNA was sodium bisulphite modified using the EZ 
DNA Methylation-GoldTM Kit (Zymo Research, Orange, CA, USA) according to the 
manufacturer’s instructions.  
Briefly, the sample volume containing 1000 ng of DNA was diluted in sterile water 
up to 20 µL of total volume in a PCR tube. To each tube was added 130 µL of CT 
Conversion Reagent and then incubated in a GeneAmp PCR System 2700 thermal 
cycler (Applied Biosystems, USA) at 98°C for 10 minutes and then at 64°C for 3 cycles 
of 60 minutes each. After, it can be at 4°C up to eighteen hours. 
Samples were transferred to a Zymo-Spin IC column already containing 600 µL 
of M-binding buffer and centrifuged at 10,000 rpm for 30 seconds. Next, the column was 
washed with 100 µL of M-Wash buffer and once again centrifuged at 10,000 rpm for 30 
seconds. The column was incubated at room temperature with 200 µL of M-
Desulphonation buffer for 20 minutes in order to desulphonate the sample. After the 
incubation, the columns were centrifuged at 10,000 rpm for 30 seconds followed by two 
washing steps with 200 µL of M-Wash buffer and centrifugations at 10,000 rpm for 30 
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seconds. One last centrifugation at 10,000 rpm for 30 seconds was performed to 
completely dry the column. 
The column was removed from the collection tube and placed in a 1.5 mL tube. 
The modified DNA was eluted by incubating the column with 30 µL of sterile distilled 
water for 5 minutes at room temperature followed by a centrifugation at 12,000 rpm for 
30 seconds. This last step was repeated allowing a final volume of 60 µL of modified 
DNA for each sample. Bisulfite modified DNA was stored at -80°C until further use. 
CpGenomeTM Universal Methylated DNA (Merck Millipore, Germany) was also 
modified, using the guidelines described above and eluted in a total of 20 µL of sterile 
distilled water. 
 
Quantitative DNA Methylation analysis using qMSP  
 
The methylation levels of the selected genes were assessed using quantitative 
methylation specific PCR (qMSP). The modified DNA was used as template and a set of 
primers designed specifically for bisulfite-converted DNA were used for each one of the 
target genes: APC, IGF2, MGMT, MLH1, RASSF1A and SEPT9 (Table 7). 
Quantitative methylation specific PCR is a highly sensitive and specific method 
that when compared to conventional PCR assays, allows an accurate and high sensitive 
DNA concentration determination [92]. Moreover, the obtain results can be either 
qualitative or quantitative, showing the present or absence of the DNA sequence (Figure 
10) of interest and when it is present, gives a relative quantification [92].   
 
 
Figure 10 – Scheme explaining methylation-specific PCR in the presence or absence of methylation using the 
appropriate primers  (Adapted from [91]). 
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For the amplicon detection was used a double-stranded (ds) DNA-intercalating 
agent (SYBR Green I). By this method, the intensity of the fluorescence signal is 
therefore dependent on the quantity of dsDNA present in the reaction. The main 
advantage of this detection method is being relatively cheap and that can be used with 
any pair of primers for any target, and the disadvantage is not being specific, since the 
dye binds to all dsDNAs formed during the PCR reaction [92, 93]. To ensure that the 
fluorescence observed was specific and not due to cross dimer of primers, the melting 
curve was also evaluated.  
The quantification depends on the DNA input, and for this reason, to estimate the 
input DNA quantity, the control gene ACTβ was used for normalization [94].  
Modified CpGenomeTM Universal Methylated DNA was used to create five serial 
dilutions by a 5x dilution factor. These serial dilutions were used to generate a standard 
curve allowing absolute quantification as well as ascertaining PCR efficiency. 
The reactions were carried out in 384-well plates (4titude, UK) using LightCycler 
480 II (Roche, Germany). Two µL of modified DNA, 5 µL of KAPA SYBR FAST qPCR 
Master Mix (Kapa Biosystems, USA), 0.4 µL (ACTβ) or 0.3 µL (target gene) 10 µM 
primers (F+R) and 2.6 µL or 2,7 µL of sterile distilled water, were added per well. All the 
samples were run in triplicates while the standards and negative control were run in 
duplicates. The primer sequences used for each gene are displayed on Table 7. 
 
Table 7 – Primers sequence used and qMSP condition for each one of the target genes. 
Gene 
Forward (F) 
5’-3’ 
Reverse (R) 
5’-3’ 
Annealing 
Temperature 
(°C) 
Concentration 
(µM) 
ACTβ 
TGGTGATGGAGGAGGTTT
AGTAAGT 
AACCAATAAAACCTACTC
CTCCCTTAA 
60 0.4 
APC 
TGTGTTTTATTGCGGAGT
GC 
CACATATCGATCACGTAC
GC 
62 0.3 
IGF2 
CGTCGTTTTTTATTGGTTT
C 
CACACGAATAACCCGCCT 60 0.3 
MGMT 
TTTCGACGTTCGTAGGTT
TTCGC 
GCACTCTTCCGAAAACGA
AACG 
60 0.3 
MLH1 
CGTTATATATCGTTCGTA
GTATTCGTGTTT 
CTATCGCCGCCTCATCGT 62 0.3 
RASSF1A 
AGCGAAGTACGGGTTTAA
TC 
ACACGCTCCAACCGAATA 60 0.3 
SEPT9 
TTAGTTAGCGCGTAGGGT
TC 
ACCTTCGAAATCCGAAAT
AA 
60 0.3 
 
The PCR program consisted in 1 cycle at 95°C for 3 minutes (for enzyme 
activation), followed by 45 cycles at 95°C with 3 seconds each (for DNA denaturation) 
and 1 last cycle at 60°C or 62°C (see Table 7) for 30 seconds (for annealing, extension 
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and data acquisition). In the end, the program assesses the melting curve of all the 
products formed during the PCR reaction. 
All the plates showed 95-100% efficiency and all the standard curves had a slope 
within -3.33 and -3.92. The plates from the same gene had equal efficiency or the 
difference between them was less than 1%. For the samples, the standard deviation was 
always less than 0.38, considering at least two of the three replicates. 
Considering the results obtain from qMSP, the Relative Methylation Levels, for 
each sample, were calculated as the ratio between the target gene mean quantity and 
the reference gene mean quantity, multiplied by one thousand. 
 
Statistical analysis 
 
Statistical analysis was performed using SPSS Statistics 22 (IBM, USA). 
The gene methylation levels and clinical parameters were compared within 
groups using non-parametric tests. It was used Mann-Whitney U test for comparisons 
between two groups and Kruskall-Wallis test for comparisons between three or more 
groups. A P-value <0.05 was considered statistically significant. 
For diagnosis analysis were only considered the 145 CRC cases that didn’t had 
any treatment prior to surgery. For most of the analysis the cases were divided by tumor 
location, colon (proximal and distal) and rectum. 
To evaluate the biomarkers performance in terms of diagnosis, ROC curves were 
built for each one of them. Next, parameters as specificity and sensitivity were 
determined for the individual biomarkers. Forward and backward stepwise elimination 
using a binary logistic regression was performed to select biomarkers in the final model. 
A ROC curve for the final model was built and the correspondent specificity and 
sensitivity was calculated. For this last task, the panel was considered as positive for a 
specific sample when at least one of the genes were positive in the individual model. 
Still for diagnosis evaluation, the positive predictive value (PPV) and negative 
predictive value (NPV) were computed according to the following formulation: PPV = true 
positives/all positives and NPV = true negatives/all negatives. 
The disease-free survival (DFS) and disease-specific survival (DSS) analysis 
was performed in order to assess the biomarkers’ prognosis value. At first, it was used 
the Kaplan-Meier method, using the two-sided log-rank test to compare the survival 
curves. Then, the Cox model was fitted to assess the prognostic value of the clinical 
parameters and methylation status of the selected genes. Univariable test was used to 
assess the contribution of each variable by determining their Hazard ratios (HR), followed 
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by a multivariable test considering a group of clinical parameters. For the multivariable 
test, all the variables with a significant association, with DFS or DSS, in univariable 
analysis were included.  
For the prognosis analysis, the methylation levels were divided by 25th percentile 
for IGF2 and 75th percentile for all the other genes. For IGF2, methylation levels under 
the percentile were called hypomethylated and above it, by non-hypomethylated. For all 
the remaining genes (MGMT, MLH1, RASSF1A, SEPT9), methylation levels above the 
percentile were considered hypermethylated and non-hypermethylated, when inferior. 
The non-hypermethylated was considered the reference group.  
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Results 
 
Clinical dataset 
 
A total of 214 patients, diagnosed with CRC between 2000 and 2012, with the 
exception of two cases, one from 1994 and another from 1997, were included in this 
study, except for one patient that was lost to follow-up. The cohort comprised: 110 colon 
cancer patients, and 104 rectum cancer patients (Table 8 and Table 9). The relevant 
clinical information for the 50 normal samples are displayed in Table 10. 
 
Table 8 – Clinicopathologic features of CRC patients by tumor location.  
Characteristic Total (n = 214) Colon (n = 110) Rectum (n = 104) 
Age (years)    
Mean 60.35 ± 0.66 60.82 ± 0.973 59.80 ± 0.898 
Range 25-80 25-80 31-80 
Gender    
Female 74 (34.6%) 42 (38.2%) 32 (30.8%) 
Male 140 (65.4%) 68 (61.8%) 72 (69.2%) 
Stage    
I and II 52 (24.3%) 24 (21.8%) 28 (26.9%) 
III 52 (24.3%) 20 (18.2%) 32 (30.8%) 
IV 108 (50.5%) 64 (58.2%) 44 (42.3%) 
Unknown 2 (0.9%) 2 (1.8%) - 
Tumor differentiation    
Well 4 (1.9%) 1 (0.9%) 3 (2.9%) 
Moderate 123 (57.5%) 79 (71.8%) 44 (42.3%) 
Poor 5 (2.3%) 4 (3.6%) 1 (1.0%) 
Not Assessable 82 (38.3%) 26 (23.6%) 56 (53.8%) 
Histology    
Mucinous 16 (7.5%) 12 (10.9%) 4 (3.8%) 
Other 198 (92.5%) 98 (89.1%) 100 (96.2%) 
KRAS mutation    
Wildtype 116 (54.2%) 60 (54.5%) 56 (53.85%) 
Mutated 84 (39.3%) 46 (41.8%) 38 (36.54%) 
Was not assessed 14 (6.5%) 4 (3.6%) 10 (9.61%) 
MSI    
MSI-H 8 (3.7%) 8 (7.3%) 0 (0%) 
MSI-L or MSS 206 (96.3%) 102 (92.7%) 104 (100%) 
Neoadjuvant treatment    
Yes 69 (32.2%) 16 (14.5%) 53 (51.0%) 
No 145 (67.8%) 94 (85.5%) 51 (49.0%) 
Adjuvant treatment    
Yes 171 (80.0%) 89 (80.9%) 82 (78.8%) 
No 45 (20.0%) 21 (19.1%) 22 (21.2%) 
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Table 9 – Number of cases by tumor location: rectum, distal or proximal colon.  
Tumor Location Total (n = 214) 
Proximal colon 37 (17.3%) 
Distal colon 73 (34.1%) 
Rectum 104 (48.6%) 
 
 
Table 10 – Basic features of Normal colon/rectum samples used. 
Characteristic CRN (n = 50) 
Age (years)  
Mean 57.50 ± 2.15 
Range 18-85 
Gender  
Female 32 (64.0%) 
Male 18 (36.0%) 
Tissue Location  
Proximal colon 19 (38.0%) 
Distal colon 16 (32.0%) 
Rectum 6 (12.0%) 
Not Assessable 9 (18.0%) 
 
 
Assessment in clinical samples  
 
The selected genes’ methylation levels were assessed for all the CRC and CRN 
samples using qMSP. For SEPT9, RASSF1A, MGMT and APC, relative methylation 
levels were significantly higher in CRC compared to normal tissues (Figure 11), whereas 
IGF2 relative methylation levels were significantly lower in CRC. Specifically, by location, 
SEPT9, RASSF1A and MGMT methylation levels were significantly higher in colon 
cancer patients, whereas SEPT9, MGMT and APC were significantly hypermethylated 
in rectum cancer, compared to CRN (Figure 12). Similar results to colon were observed 
when a separated analysis of proximal and distal colon was performed (Mann-Whitney 
U Test, P<0.05).  
Moreover, slightly higher SEPT9 methylation levels were found in colon cancer 
patients than in rectum cancer patients (Mann-Whitney U Test, P=0.021). No significant 
association was found between genes’ methylation levels and patients’ age. 
MGMT and MLH1 methylation levels were marginally, but significantly higher in 
female patients compared with males both in colon and rectum samples (P=0.048 and 
P=0.049, P=0.007 and P=0.010, respectively). 
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Figure 11 –  Box-plots of (A) IGF2, (B) SEPT9, (C) RASSF1A, (D) MGMT, (E) APC, (F) MLH1 promoter methylation 
levels in normal (CRN) and neoplastic tissue (CRC). (Mann-Whitney U Test, * P<0.05; ** P<0.01). 
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Figure 12 – Box-plots for (A) IGF2, (B) SEPT9, (C) RASSF1A, (D) MGMT, (E) APC, (F) MLH1 promoter methylation 
levels in normal (CRN) and neoplastic tissue (CRC), by location (Mann-Whitney U Test, * P<0.01). 
 
The methylation levels for each gene were compared for the most relevant 
features considering colon and rectum samples in separated (Appendix 3: Table 22 and 
Table 23). Neoadjuvant treated rectum cancer patients showed significantly lower 
SEPT9 and MGMT methylation levels (P=0.002 and P=0.012, respectively).  
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MSI status assessed by immunohistochemistry showed that 8 cases were MSI-
H, whereas 206 were MSI-L or MSS. Except for APC promoter (P=0.008), no significant 
differences were found for methylation levels between MSI-H and MSI-L/MSS (Table 11, 
Figure 13).  
 
Table 11 – Comparative analysis of genes methylation levels according to the MSI status (MSI-H or MSI-L/MSS). 
Gene IGF2 SEPT9 RASSF1A MGMT APC MLH1 
P 0.141 0.816 0.080 0.701 0.008 0.368 
Test Mann-Whitney U Test 
 
 
 
Figure 13 – Box-plot of APC Methylation levels across MSI-H and MSI-L or MSS samples. Mann-Whitney U Test, 
P=0.008. 
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Evaluation of the diagnostic value 
 
The best performance for CRC detection was achieved by SEPT9, with 85.5% 
sensitivity, 94.0% specificity, 97.6% PPV and 69.1% NPV.  
 
Table 12 – Performance of epigenetic biomarkers for detection of CRC in tissue. Sensitivity and specificity values 
(%) for the individual genes and panels. n stand for number of positive cases and N for the total of cases tested. 
  Sensitivity (n/N) Specificity (n/N) AUC 
SEPT9 85.5 (124/145) 94.0 (3/50) 0.950 
MGMT 77.2 (112/145) 84.0 (8/50) 0.894 
RASSF1A 33.1 (48/145) 90.0 (5/50) 0.621 
IGF2 - hypomethylation 58.6 (85/145) 64.0 (18/50) 0.599 
APC 35.2 (51/145) 90.0 (5/50) 0.651 
MLH1 13.8 (20/145) 97.9 (1/48) 0.496 
Panel      
SEPT9, MGMT 93.8 (136/145) 82.0 (9/50) 0.964 
SEPT9, MGMT, RASSF1A 96.6 (140/145) 74.0 (13/50) 0.970 
SEPT9, MGMT, APC 95.2 (138/145) 76.0 (12/50) 0.965 
 
Considering gene panels, the best performance was attained for 
SEPT9/MGMT/RASSF1A, with 96.6% sensitivity and 74.0% specificity (Figure 14). The 
highest values of PPV and NPV were obtained with SEPT9/MGMT/APC panel (92.0% 
and 87.3%, respectively) (Table 12, Table 13). 
 
Table 13 – Positive and negative predictive values for SEPT9 alone and for the three more relevant panels. 
Panel PPV (%) NPV (%) 
SEPT9 97.6 69.1 
SEPT9, MGMT 93.8 82.0 
SEPT9, MGMT, RASSF1A 91.5 72.5 
SEPT9, MGMT, APC 92.0 87.3 
 
ROC curve analysis was performed for all the selected genes, using only the 
cases without any treatment prior to surgery (n=145). The best performance was found 
for SEPT9 followed by MGMT (AUCs of 0.950 and 0.894, respectively). Considering the 
gene panels, SEPT9/MGMT/RASSF1A methylation levels disclosed the best 
performance with 0.970 AUC. 
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Figure 14 – ROC curves for promoter methylation of SEPT9 alone and SEPT9/MGMT/RASSF1A panel considering 
the CRC cases without any treatment prior to surgery. 
 
The positive detection rate was calculated according with lesion locations and 
CRC stages. Overall, the panel SEPT9, MGMT, RASSF1A performed better to detect 
cancer in all locations and stages of the disease (Table 14).  
 
Table 14 – Positive detection rate for location groups and stage of disease.  n stand for number of positive cases 
and N for the total of cases tested. Considering 145 cases in total. 
Positive detection Rate [%(n/N)] 
Diagnosis Group SEPT9 
SEPT9, MGMT, 
RASSF1A 
SEPT9, MGMT, 
APC 
Location    
Colon: 84.0 (79/94) 95.7 (90/94) 93.6 (88/94) 
Proximal 86.7 (26/30) 93.3 (28/30) 93.3 (28/30) 
Distal 82.8 (53/64) 96.9 (62/64) 93.8 (60/64) 
Rectum 88.2 (45/51) 98.0 (50/51) 98.0 (50/51) 
Stage    
Stage I and II 91.4 (32/35) 100 (35/35) 97.1 (34/35) 
Stage III 80.0 (28/35) 94.2 (33/35) 91.4 (32/35) 
Stage IV 84.9 (62/73) 95.9 (70/73) 95.9 (70/73) 
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Evaluation of Prognostic Value 
 
To define the prognostic value of selected genes’ promoter methylation in CRC, 
disease-free survival (DFS) and disease-specific survival (DSS) were computed based 
on clinical and epigenetic variables (Appendix 4: Table 24 and Table 25). The median 
follow-up in this cohort was 4.32 years (range from 0.41 to 17.68 years). At the time of 
the last follow-up, 187 patients (87.4%) deceased from CRC, 12 (5.6%) are still being 
treated for CRC and 15 (7.0%) are considered disease-free.  
Regarding DFS, none of the genes showed significant association with 
prognosis. As for the DSS, higher SEPT9 and MLH1 methylation levels were significantly 
associated with better prognosis, P=0.054 and P=0.017, respectively (Figure 15).  
A multivariable analysis, using Cox regression, was also performed to assess the 
real influence of clinicopathological and epigenetic features in predicting DFS and DSS 
(Table 15 and Table 16). Hypermethylation of SEPT9 and MLH1 was associated with 
better prognosis, while larger primary tumor and age were shown to be independent 
prognostic factors for DFS. 
Higher SEPT9 and MLH1 methylation levels independently predicted improved 
DFS (P=0.031 and P=0.027, respectively) and DSS (P=0.031 and P=0.033, respectively) 
(Figure 16 and Figure 17). Primary tumor (pT), regional lymph nodes (pN) and age were 
also shown to independently predict DSS. 
 
 
Figure 15 – Kaplan-Meier analysis with the association between DSS and methylation levels in SEPT9 (A) and 
MLH1 (B). P was assessed by Log-Rank Test. (n=214) 
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Table 15 – Multivariable analysis using Cox regression for Disease-free survival (DFS) (n=214). 
 Multivariable analysis HR (95% CI) P 
SEPT9 Hyper 0.603 (0.381-0.954) 0.031 
MLH1 Hyper 0.604 (0.386-0.945) 0.027 
Primary Tumor 
(pT) 
T1 and T2 1 (referent) <0.001 
T3 1.664 (0.908-3.049) 0.099 
T4a and T4b 13.253 (3.708-47.364) <0.001 
Age group 
18-57 1 (referent) 0.018 
58-65 1.993 (1.219-3.259) 0.006 
66-85 1.704 (0.997-2.912) 0.051 
 
 
Figure 16 – Kaplan-Meier analysis with the association between DFS and SEPT9 (A) and MLH1 (B) methylation 
levels, pathological stage (C) and Age (D). P was assessed by Log-Rank Test. (n=214) 
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Table 16 – Multivariable analysis using Cox regression to assess the potential of SEPT9 and MLH1 methylation 
levels, in addiction to clinical features in prediction of Disease-specific survival (DSS). n=214. 
 Multivariable analysis HR (95% CI) P 
SEPT9 Hyper 0.654 (0.445-0.962) 0.031 
MLH1 Hyper 0.672 (0.467-0.968) 0.033 
Stage 
I and II  1 (referent) 0.106 
III 0.813 (0.423-1.563) 0.535 
IV 1.567 (0.795-3.087) 0.195 
Primary Tumor 
(pT) 
T1 and T2 1 (referent) 0.005 
T3 0.813 (0.496-1.334) 0.413 
T4a and T4b 2.189 (1.054-4.545) 0.036 
Regional Lymph 
Nodes (pN) 
N0 1 (referent) 0.015 
N1 a, b, c 0.907 (0.539-1.528) 0.714 
N2 a,b 1.798 (1.029-3.139) 0.039 
Distant 
Metastasis (M) 
M0 1 (referent) 0.680 
M1a 1.121 (0.652-1.926) 0.680 
M1b - - 
Neoadjuvant 
Treatment 
No 1 (referent)  - 
Yes 1.283 (0.904-1.821) 0.163 
Age group 
18-57 1 (referent) <0.001 
58-65 2.035 (1.374-3.016) <0.001 
66-85 2.297 (1.548-3.407) <0.001 
Colon 
Rectum 1 (referent) 0.151 
Distal 0.969 (0.668-1.406) 0.868 
Proximal 1.504 (0.939-2.409) 0.090 
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Figure 17 – Kaplan-Meier analysis with the association between DSS with primary tumor (A), regional lymph 
nodes (B) and age group (C). P was assessed by Log-Rank Test. (n=214) 
 
To evaluate whether there was any specific association between selected genes 
methylation and tumor location (Appendix 4: Table 26, Table 27, Table 28, Table 29), 
univariable and multivariable analysis of DFS and DSS were also constructed for Colon 
and Rectum cancer independently (Table 17 and Table 18). 
Aberrant methylation was not associated with DFS for any of the defined tumors’ 
locations. Nonetheless, pT4 colon tumors associated with a shorter DFS (HR=11.44, 
95% CI: 1.947- 67.229), whereas in rectum tumors, female gender associated with 
longer DFS (HR=0.296, 95% CI: 0.149 - 0.589). 
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Table 17 – Multivariable analysis using Cox regression to assess the potential of SEPT9 and MLH1 methylation 
levels and of clinical features in Disease-specific survival (DSS) in colon cancer patients (n=110). 
Multivariable analysis 
Colon 
HR (95% CI) P 
SEPT9 Hyper 0.472 (0.275-0.809) 0.006 
MLH1 Hyper 0.513 (0.302-0.873) 0.014 
Stage 
I and II 1 (referent) 0.720 
III 0.824 (0.396-1.716) 0.605 
IV 1.135 (0.517-2.490) 0.753 
Primary Tumor 
(pT) 
T1 and T2 1 (referent) 0.001 
T3 1.334 (0.495-3.594) 0.568 
T4a and T4b 4.643 (1.454-14.828) 0.010 
Distant 
Metastasis (M) 
M0 1 (referent) - 
M1a 1.251 (0.633-2.470) 0.520 
M1b - - 
Neoadjuvant 
Treatment 
No 1 (referent) - 
Yes 1.083 (0.593-1.976) 0.796 
Age group 
18-57 1 (referent) 0.014 
58-65 1.976 (1.071-3.647) 0.029 
66-85 2.258 (1.293-3.944) 0.004 
Colon 
Proximal 1 (referent) - 
Distal 0.554 (0.345-0.891) 0.015 
 
Regarding, DSS, in colon cancer, SEPT9 and MLH1 methylation levels 
significantly associated with better prognosis, whereas in rectum significance was only 
reached for SEPT9 methylation.  
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Table 18 – Multivariable analysis using Cox regression to assess the potential of SEPT9 and MLH1 methylation 
levels, in addiction to clinical features in prediction of Disease-specific survival (DSS) on rectum. n=104. 
Multivariable analysis (DSS) 
Rectum 
HR (95% CI) P 
SEPT9 Hyper 0.564 (0.319-0.996) 0.049 
MLH1 Hyper 1.044 (0.615-1.773) 0.872 
Stage 
I and II  1 (referent) 0.124 
III 1.120 (0.632-1.984) 0.699 
IV 2.705 (1.032-7.091) 0.043 
Distant 
Metastasis (M) 
M0 1 (referent) - 
M1a 0.813 (0.325-2.034) 0.658 
M1b - - 
Age group 
18-57 1 (referent) 0.040 
58-65 1.889 (1.100-3.245) 0.021 
66-85 1.848 (1.045-3.268) 0.035 
 
 
 
 
Figure 18 – Kaplan-Meier analysis with the association between DSS and methylation levels in MLH1 on CRC 
located in colon (A) and in rectum (B). P was assessed by Log-Rank Test. (n=110 for colon and n=104 for rectum) 
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Discussion 
 
CRC is one of the most common and deadly malignancies worldwide [4]. 
Although biopsy is needed for histological confirmation, CRC’s screening for early-
stages can only be accomplished by colonoscopy presently. This is an invasive and 
expensive procedure, despite being essential in diagnosis of several gastrointestinal 
diseases, including CRC. Currently, no other accurate diagnostic alternative has been 
found.  
Nevertheless, research efforts has been made in this field and the most promising 
type of biomarkers for CRC’s detection have been shown to be based on aberrant 
methylation of several cancer–related genes [34]. Indeed, some DNA methylation-based 
biomarkers were already approved by FDA, including ColoVantage®, Epi proColon® and 
ColoSure®. While the former two are based on SEPT9 methylation [62, 63], the latter is 
based on Vimentin methylation [65]. The value of SEPT9 promoter methylation in CRC’s 
detection has been recently questioned, however, by a recent study that showed only 
48.2% sensitivity and 91.5% specificity [64]. As for Vimentin methylation, the use of this 
test needs to be combined with colonoscopy since its sensitivity is variable, ranging from 
38-88% [65, 66]. 
In this context, this dissertation aimed to find and validate a novel panel of 
biomarkers based on DNA promoter methylation. After literature review, six genes were 
selected and then validated in CRC’s tissue samples. Those included two tumor 
suppressor genes, APC and RASSF1A, a gene implicated in mismatch repair, MLH1, 
one that encodes for a normally imprinted fetal growth factor, IGF2, the septin gene, 
SEPT9, and finally, a DNA repair gene, MGMT. 
Excepting for MLH1, the majority of the selected genes were able to distinguish 
CRC from CRN samples. From these, IGF2 methylation levels were slightly lower in CRC 
than CRN, being in accordance with reported data [79], whereas the remainder  showed 
significantly higher methylation levels on CRC, as it was expected. Considering colon 
and rectum cancer separately, only SEPT9, MGMT and RASSF1A were able to 
distinguish CRC from CRN in colon and SEPT9, MGMT and APC in rectum. Therefore, 
DNA methylation in colon and rectum tissues revealed a slightly different signature, 
differing only on general cancer genes, APC and RASSF1A, whereas SEPT9 and MGMT 
methylation was present in both locations. 
Considering the methylation levels of CRC samples between the two locations, 
colon and rectum, no significant differences were found between them, with the 
exception of SEPT9 which had a slightly higher methylation on colon samples. Thus, 
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location does not seem a relevant factor that may limit the ability of these markers to 
identify CRC. 
MSI-H has been reported to be due to defects in the DNA MMR system [40]. This 
system includes genes like MLH1, MSH2, MSH6 and PMS2 whose expression was 
screened by immunohistochemistry. Therefore, assuming that the lack of expression, in 
any of these genes, represents a defect on this system, one may assume that these 
defects possibly lead to MSI-H pathway and so, the samples on this situation will be 
considered as MSI-H, whereas the remaining samples most likely represent MSI-L or 
MSS cases. Knowing that the two types of instability are mutually exclusive, a tumor 
fitting into the CIN pathway most likely would be MSS [41, 42], therefore, the group MSI-
L/MSS would be highly concentrated on samples falling into CIN pathway. The group 
MSI-L/MSS will, in a grossly way, represent CIN behavior. 
Between the two categories, MSI-H and MSI-L/MSS, only APC showed 
differences in methylation levels (P=0.008). All the other genes did not show differences 
in methylation levels and so it can be assumed that, in a general way, the selected genes 
were able to detect CRC both in MSI or CIN pathways. Thus, only remains to know if the 
same is verified in samples fitting the CIMP pathway. The CIMP characterization is being 
done in a parallel project.  
In this cohort, it was observed that, for rectum only, SEPT9 had higher 
methylation levels for stage IV when compared to stage I, II or III (P=0.001) and for both 
SEPT9 and MGMT, methylation levels were lower for patients that received neoadjuvant 
treatment (P=0.002 and P=0.012, respectively). In fact, there are several studies 
reporting and demonstrating that ionizing radiation exposure could affect DNA 
methylation patterns. The most frequently reported radiation-induced situations are 
global hypomethylation, loss of methylation, paralleled with a decrease in expression 
levels of methyltransferases and methyl CpG binding proteins [95, 96]. In colon cancer 
a trend for radiation-induced hypomethylation had also been reported [97].  
Methylation levels observed for MGMT and MLH1 were higher in female both in 
colon and rectum samples, a finding that might be related with the reported higher MLH1 
promoter methylation in female patients already reported in a meta-analysis study [98]. 
For MLH1 or any of the other genes, no significant differences were found among 
the age groups, suggesting that the methylation sites analyzed do not endure significant 
age-related changes in DNA methylation levels. Age-related methylation in colorectal 
tissues has been extensively, although this phenomenon is not exclusive of colorectal 
tissues, as other human tissues also display this type of methylation [99, 100]. The 
possibility of hypermethylation observed in cancer be age-related was raise, but it was 
concluded that there were two types of methylation in cancer, the age-related 
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methylation, which precedes neoplastic transformation, and cancer-related methylation, 
which is totally cancer-related [99]. No correlation between age and selected genes 
methylation was found in the samples of this cohort, which suggests that the methylation 
found most certainly corresponds to the cancer-related type. 
The gene with the best performance in terms of diagnosis was SEPT9 followed 
by MGMT. SEPT9 showed 85.5% sensitivity and 94.0% specificity, which is not very 
different from the data presented by the trademark assays using SEPT9 methylation [62, 
101]. MGMT displayed a better performance, with 77.2% sensitivity and 84.0% 
specificity, which is superior to that previously reported: 46-53% sensitivity and 74-100% 
specificity, both in tissue samples [84, 102]. 
APC showed 35.2% sensitivity and 90.0% specificity which comes close to the 
47% sensitivity and 77% specificity [103], and 97% specificity [69] previously described 
by other authors. Although the results observed for RASSF1A, 33.1% sensitivity and 
90.0% specificity, differ from those reported for tissue samples (81.0% sensitivity and 
51.0% specificity [74]), it should be recalled that different methodologies were used, 
precluding direct comparisons. The values obtained to IGF2 were lower than it would be 
expected, 58.6% sensitivity and 64.0% specificity against 80.0% sensitivity and 90.0% 
specificity reported previously, although pyrosequencing was used instead of MSP [81]. 
For MLH1, with 13.8% sensitivity and 97.9% specificity, sensitivity was much lower than 
previously reported (95% [104]) using sequencing of nested MSP products, although 
specificity was similar to the one previously described, 97.0% [69] (using MSP). 
Combining SEPT9 and MGMT, an improvement of sensitivity could be reached, 
with 93.8% sensitivity, 82.0% specificity and 82.0% NPV. Adding RASSF1A to the panel 
might improve its diagnostic performance through the acquisition of good balance 
between all parameters: 96.6% sensitivity, 74.0% specificity, 91.5% PPV and 72.5% 
NPV.  
The SEPT9/MGMT/RASSF1A panel was able to detect CRC both in colon 
(proximal and distal) and rectum with a positive detection rate above 90%, more exactly, 
95.7% for colon and 98.0% for rectum. Besides, the panel was also able to detect equally 
tumors at any disease stage, with a positive detection rate of 100% for stage I and II, 
94.2% for stage III and 95.9% for stage IV. The panel displayed better positive detection 
rates than SEPT9 alone, supporting the theory that a panel has a better performance on 
CRC diagnosis.  
Some of the analyzed genes in this study displayed prognostic value. Indeed, 
hypermethylation of SEPT9 (DFS HR=0.031, and DSS HR=0.031) and MLH1 (DFS 
HR=0.027, and DSS HR=0.033) were associated with a better prognosis, i.e., increased 
DFS and DSS. For DSS they were also independent prognostic factors. Considering 
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colon and rectum separately, none of the genes had prognosis value for DFS, as for 
DSS, although hypermethylation of SEPT9 was an independent factor for colon 
(P=0.006) and it was associated with a better prognosis on both locations. 
Hypermethylation of MLH1 was an independent factor associated with a better prognosis 
exclusively for tumors located on colon (P=0.014). For rectum, no association with 
prognosis was found for MLH1 methylation. MGMT did not show any association with 
CRC prognosis as already reported in a meta-analysis that included fourteen studies 
[105]. 
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Conclusions and Future Perspectives 
 
Globally, for detection/diagnostic purposes, our results parallel the published 
data, mostly regarding SEPT9, MGMT and RASSF1A promoter methylation in CRC.  
The gene with best diagnostic value was SEPT9, similar to some published data, 
supporting SEPT9‘s promoter methylation as a promising biomarker, showing high 
sensitivity for CRC. In addition, these results suggest that MGMT is a very good 
biomarker as well, and when put together with SEPT9, the CRC detection sensitivity is 
highly improved. The addition of RASSF1A to the panel contributes for the cancer 
baseline detection, improving the panel robustness. Thus, a panel combining 
SEPT9/MGMT/RASSF1A might provide superior performance than currently available 
epigenetic-based biomarkers for CRC. This shows that it is possible to improve CRC 
detection efficacy by combining some well-known biomarkers already reported 
individually.   
Methylation levels in tissues following MSI and CIN pathways were not 
significantly different in the two major biomarkers of the panel (SEPT9 and MGMT) which 
suggest that CRC detection by this panel will not be molecular pathway’s dependent, at 
least for these two paths. Remains to know if the same is verified for CIMP.  
This dissertation demonstrated that promoter methylation of 
SEPT9/MGMT/RASSF1A might constitute a useful panel for CRC identification. 
However, to be used in a non-invasive setting, it must be tested in easily obtainable 
biofluids, especially blood. However, the specificity of this approach will be challenged 
by the possibility that other cancers, especially the most common (e.g., gastric, 
pulmonary, pancreatic) might also share similar DNA methylation signatures. Thus, 
future studies should also include as “controls” not only healthy individuals, but also 
carriers of other cancer types. 
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Appendix 1: Genes Selection - Literature 
review 
 
In order to find genes with relevance in this matter, a literature review was made. 
For start, it was compiled a list of genes reported to be methylated in CRC, only the ones 
with significant cohorts. The sample type used for methylation assessment, sensitivity 
and specificity reported in each article was annotated in the same list. All this information 
was taken into account to the selection of potential genes (Table 19).  
However, displaying methylation on CRC cases was not enough, it was needed 
that the selected genes were specific for CRC, and so, have a very low frequency in 
other malignancies. For this reason, for some of the genes, it was search the frequency 
observed in other types of cancer. On Table 20 is shown the results of this search, 
displaying information about the type of cancer in which methylation is also present, its 
frequency, the specimen type and the sample size.  
The aim of this study is not only found good biomarkers individually but also to 
find a panel with a great performance. Therefore, a search for panels used in methylation 
analysis was made in order to assess the ones that had already been reported. 
Information about the sensitivity, specificity, specimen type and method used was 
collected when available, Table 21. 
 Considering all this search, some genes demonstrated potential usefulness, not 
only to detect globally cancer, such as APC and RASSF1A, but also to detect CRC, such 
as MLH1, MGMT, SEPT9 and IGF2.  
The selection of the gene location to perform this study was a very careful one. 
For some of the genes were used the same primers as described in literature, for others, 
the primers were design specifically for a very exact location.  
In order to study the promoter methylation of APC, primers in the same gene 
location that previous studies [68, 103, 106] were design. The primers used for 
RASSF1A were designed in the same gene region reported by other authors [74, 103, 
107]. 
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Table 19 – List of genes reported to be methylated in CRC. IGF2 is described to be hypomethylated. * 
hypomethylation ≤35%. 
Gene Sensitivity (%) Specificity (%) Specimen Type References 
DCLK1 82 100 Tissue [108] 
SEPT9 69 86 Plasma [109] 
TMEFF2 
65 69 Plasma [109] 
- 100 Plasma [110] 
SFRP1 52 92 Stool [111] 
SFRP2 
93 100 Tissue [102] 
94 96 Stool [102] 
57 90 Stool [112] 
MGMT 
53 100 Tissue [102] 
48 100 Stool [102] 
- 96 Tissue [69] 
- 100 Plasma [69] 
46 74 Tissue [84] 
RASSF2A 
60  100 Tissue [69] 
- 100 Plasma [69] 
84 98 Stool [113] 
73 88 Tissue [114] 
70 100 Tissue [115] 
HLTF 
- 98 Tissue [69] 
41 93 Plasma [69] 
52 82 Tissue [103] 
MLH1 
95 - Tissue [104] 
- 97 Tissue [69] 
- 100 Plasma [69] 
CDKN2A 
73 - Tissue [116] 
71 - Plasma [116] 
- 97 Tissue [69] 
- 100 Plasma [69] 
NGFR 51 84 Plasma [109] 
HPP1 
73 100 Tissue [102] 
71 100 Stool [102] 
HIC1 42 98 Stool [117] 
UNC5C 68 - Tissue [118] 
DCC 56 - Tissue [118] 
RUNX3 
75.6 76.3 Tissue [119] 
34 - Tissue [120] 
Wif-1 
74 98 Tissue 
[69] 
37 91 Plasma 
GATA4 
70 94 Tissue [103] 
51 93 Stool [103] 
43 95 Stool [112] 
GATA5 
79 87 Tissue [103] 
84 83 Stool [112] 
OSMR 32 - Tissue [118] 
DFNA5 34 - Tissue [66] 
RASSF1A 81 51 Tissue [74] 
IGF2* 80 90 Tissue [81] 
VIM 41 85 Stool [112] 
APC 
- 97 Tissue [69] 
- 100 Plasma [69] 
47 77 Tissue [103] 
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Table 20 – Methylation frequency in other malignancies for some of the previous genes.  
Gene Cancer type 
Freq. 
(%) 
Specimen 
type 
Sample 
size 
References 
RASSF2A Gastric carcinoma  19 Fecal n=21 [113] 
IGF2 
Colorectal cancer 80 Tissue n=42 
[81] 
Breast cancer 33 Tissue n=22 
GATA4 
Lung cancer 67 Tissue n=63 [121] 
Esophageal adenocarcinoma  71 Tissue n=44 [122] 
GATA5 
Lung cancer 41 Tissue n=63 [121] 
Esophageal adenocarcinoma 55 Tissue n=44 [122] 
Wif-1 
Esophageal cancer 80 Tissue n=20 
[123] 
Gastric cancer 74.2 Tissue n=31 
Colorectal cancer  82 Tissue n=50 
Pancreatic cancer 75 Tissue n=8 
Lung cancer 83 Tissue n=18 [124] 
RUNX3 
Breast carcinoma 47 
Plasma 
n=19 
[125] 
Non-small cell lung cancer 55 n=20 
Gastric carcinoma 100 n=4 
Pancreatic carcinoma 100 n=2 
Colorectal carcinoma 65 n=17 
Liver carcinoma 88 n=8 
Non-small cell lung cancer 25 Tissue n=101 [126] 
Breast cancer 53 Tissue n=20 [127] 
Gastric carcinoma 71 Tissue n=80 [128] 
RASSF1A 
Breast carcinoma 42 
Plasma 
n=19 
[125] 
Non-small cell lung 30 n=20 
Gastric carcinoma 25 n=4 
Pancreatic carcinoma 50 n=2 
Colorectal carcinoma 24 n=17 
Liver carcinoma 50 n=8 
Lung cancer 88 - - 
Reviewed [129] Breast cancer 95 - - 
Prostate cancer 99 - - 
Parathyroid tumor 98 Tissue n=55 [130] 
Non-small cell lung cancer 42 Tissue n=101 [126] 
APC 
Breast cancer 36 Tissue n=50 [70] 
Pancreatic acinar cell carcinoma 56 Tissue n=43 [131] 
Breast cancer 
45 Tissue n=84 
[132] 
31 Serum n=84 
Parathyroid tumor 71 Tissue n=55 [130] 
Esophageal adenocarcinoma  78 Tissue n=50 
[133] Cardiac adenocarcinoma 32 Tissue n=50 
Gastric adenocarcinoma 84 Tissue n=50 
MLH1 Endometrial carcinoma 45 Tissue n=29 [77] 
MGMT 
Oral squamous cell carcinoma 41 Tissue n=99 [89] 
Non-small cell lung cancer 14 Tissue n=101 [126] 
Gliomas 64.8 Tissue n=247 [134] 
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Table 21 – Panels of genes based on DNA methylation reported in a few studies. COBRA: Combined Bisulfite 
Restriction Analysis. Hi-SA: High-sensitivity assay for bisulfite DNA. qMSP: Quantitative Methylation-specific 
PCR. QuARTS: is a Real-time target and signal amplification technology. 
Panel of markers 
Sensitivity 
(%) 
Specificity 
(%) 
Specimen 
type 
Method Ref. 
TMEFF2; NGFR; 
SEPT9 
- - Plasma 
Microarray; 
qPCR 
[109] 
APC; MGMT; 
RASSF2A; Wif-1 
86.5 92.1 Plasma MSP [69] 
SFRP2; RASSF2 75.0 89.4 Stool COBRA, Hi-SA [113] 
BMP3; NDRG4; TFPI2; 
Vimentin 
85 89 Stool QuARTS [135] 
HPP1; HLTF; MLH1 - - Plasma MSP [136] 
UNC5C; DCC 82 - Tissue qMSP [118] 
SFRP2; HPP1; MGMT 93.7 77.1 Stool MSP [102] 
 
The promoter of MLH1 is divided into four regions, A, B, C and D, and it was 
shown that the absence of MLH1 expression was more correlated with the methylation 
within C region. Methylation of A and B regions were not specific for loss of expression 
and in D region was also a good indicator of MLH1 silencing, despite being less specific 
than C region [75, 137]. The absence of MLH1 expression is an indicator of MSI, for this 
study we already have this information by immunohistochemistry. For this motive and 
with the intent of have more information about the methylation on promoter region, the 
primers used were the same described by Widschwendter, Siegmund [138]. 
IGF2 LOI is correlated with hypomethylation at a differentially methylated region 
(DMR)-0 [79]. With the intention of studying the methylation status of DMR-0 (Figure 19), 
primers were design within this region including the only three CpGs [78, 79] on forward 
primer.  
 
 
Figure 19 – CpGs present in each DMR of IGF2. P1-P4 represent the four promotors of the gene (Adapted from 
[79]) 
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Within SEPT9 gene were found four CpG islands, one extragenic and three 
intragenic, they were designated as CGI1, CGI2, CGI3 and CGI4 (Figure 20). The only 
one described as differentially methylated in CRC is CGI3. A study by Wasserkort, 
Kalmar [82] assessing which location within CGI3 is more specific for neoplasia, tested 
three sets of primers in this region. The primers for the amplicon located centrally in CGI3 
(Figure 20) have shown the largest methylation differences between normal and 
neoplastic samples [82]. This is the target region used by diagnostic tests currently 
available for clinical application [82]. For this reason, primers within the ones used by 
this author were designed and used in the assessment of SEPT9 promoter methylation 
levels. 
 
 
Figure 20 – Genomic organization of SEPT9. Location of each CGI and the detail of CGI3 with the location of the 
three amplicons. (5) is the amplicon which the methylation was more specific for CRC detection (Adapted from 
[82]) 
 
For MGMT, the primers used were the ones described by Huang, Li [102] and 
Ramalho-Carvalho, Pires [86] which are located in the same region as primers described 
by other authors [46, 138]. The primers used were located in the promoter region in which 
methylation is more related with loss of MGMT expression [86]. 
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Appendix 2: Clinical data base construction 
 
In order to do a complete evaluation of diagnostic and prognostic value of each 
one of the selected biomarkers, clinical information of all of the cohort’s patients was 
collected and displayed in a data base. This information was mostly available on patients’ 
clinical charts on virtual or paper processes.  
Some basic information about each patient was first collected. On this data was 
included: gender, date of birth, age at diagnosis, tumor location (Rectum, Distal Colon 
and Proximal colon), confirmation of diagnosis (Adenocarcinoma), date of surgery, age 
at surgery, if the patient had neoplastic history, personal or familiar, and when applicable, 
which type of tumor is included in this history. In the location feature, proximal colon 
included tumors on cecum, ascending colon, hepatic flexure and transverse colon, while 
distal colon included tumors on splenic flexure, descending colon and sigmoid colon. 
Next, information about the tumor and specifically about the tissue used in this 
study was collected too. In these were included: histologic grade, microscopic tumor 
extension, if the surgical margins were tumor-free (proximal, distal and radial), number 
of total lymph nodes removed during surgery and how many were metastasized, if had 
metastasis ad initio and where (Liver, Lung or in other location), TNM classification 
(pathological T and N; M were pathological or clinical depending on the case), stage and 
if the patient did neoadjuvant treatment and which regimen. This data was collected take 
into account the information displayed on “staging” chapter (Introduction). Considering 
the information obtain about the Lymph nodes, the ratio of metastasized lymph nodes 
was determined. Follow-up information was also collected: current treatment (when the 
patient was still alive), if did adjuvant treatment and which regimen, if were used biologic 
agents in adjuvant therapy, if metastasized after surgery, which organ and if had local 
recurrence. Data regarding KRAS, BRAF and PIK3CA mutations, when available, was 
also collected. For the PIK3CA mutation, nothing was found.  
For prognosis analysis the information collected was for survival analysis: date of 
diagnosis, vital status and date of last follow-up or death depending on vital status; and 
for disease-free survival: date of last curative treatment, if the patient relapse, date of 
recurrence or date of follow-up/death if the patient didn’t relapse and is alive or die 
disease-free.  
Some of these features were reviewed by a pathologist to ensure its accuracy. 
 
 
 
FCUP 
DNA Methylation for detection of primary colorectal tumors 
53 
 
Appendix 3: Results I 
Table 22 – Analyses of clinical and pathological variables from Colon for each one of the genes in study (P values were obtained by Mann-Whitney Test or Kruskal-Wallis Test). 
n=110 (Colon) 
SEPT9 
methylation 
MGMT 
methylation 
RASSF1A 
methylation 
APC 
methylation 
IGF2 
methylation 
MLH1 
methylation 
Variables n Median P Median P Median P Median P Median P Median P 
Sex 
Female 42 236.448 
0.204 
48.121 
0.048 
0.000 
0.516 
13.234 
0.917 
63.036 
0.214 
2.660 
0.007 
Male 68 153.980 20.967 0.000 15.577 57.953 0.000 
Age Group 
18-56 35 166.062 
0.757 
18.274 
0.311 
0.000 
0.355 
15.490 
0.241 
58.208 
0.913 
0.000 
0.995 57-65 40 179.207 35.050 0.000 18.777 60.777 1.249 
66-85 35 217.652 22.159 0.000 9.338 60.826 1.419 
Mucinous 
histology 
No 98 212.920 
0.104 
26.536 
0.283 
0.000 
0.991 
14.801 
0.946 
58.936 
0.079 
1.342 
0.127 
Yes 12 123.236 13.176 0.000 14.409 74.254 0.000 
Stage 
I and II 24 225.064 
0.348 
41.618 
0.282 
0.000 
0.257 
15.685 
0.716 
52.354 
0.456 
1.959 
0.448 III 20 193.869 29.731 0.000 11.709 62.703 1.794 
IV 64 179.207 20.967 0.000 13.666 63.017 0.793 
Primary Tumor 
(pT) 
T1 and T2 6 397.610 
0.018 
33.907 
0.974 
0.007 
0.420 
12.281 
0.894 
56.790 
0.160 
3.189 
0.052 
T3 89 179.443 25.038 0.000 14.861 59.823 1.332 
T4 13 111.014 47.448 0.000 14.741 90.308 0.000 
Tx 2 906.720 112.569 8.981 208.568 29.109 7.980 
Regional Lymph 
Nodes (pN) 
N0 39 197.867 
0.000 
36.510 
0.554 
0.000 
0.932 
15.490 
0.682 
48.382 
0.046 
1.328 
0.836 
N1 33 251.779 20.922 0.000 9.338 64.305 1.503 
N2 36 102.014 18.592 0.000 18.229 63.488 0.000 
Nx 2 906.720 112.569 8.981 208.568 29.109 7.980 
Distant 
Metastasis (M) 
M0 44 224.365 
0.011 
38.285 
0.370 
0.000 
0.407 
15.116 
0.224 
59.743 
0.056 
1.880 
0.225 
M1 51 210.815 18.312 0.000 10.770 58.208 1.225 
M2 13 51.714 44.147 0.000 35.887 153.440 0.000 
Mx 3 906.720 112.569 8.981 208.568 29.109 7.980 
Neoadjuvant 
Treatment 
No 94 197.120 
0.514 
25.619 
0.482 
0.000 
0.165 
16.210 
0.084 
59.824 
0.536 
1.049 
0.217 
Yes 16 169.485 28.136 0.000 10.320 61.958 2.142 
KRAS Mutation: 
resistance 
NA 66 133.552 
0.064 
18.861 
0.022 
0.000 
0.067 
15.879 
0.950 
63.885 
0.688 
0.000 
0.564 
Yes 44 228.674 42.814 0.000 11.982 59.016 1.498 
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Table 23 - Analyses of clinical and pathological variables from Rectum for each one of the genes in study (P values were obtained by Mann-Whitney Test or Kruskal-Wallis Test). 
n=104 (Rectum) 
SEPT9 
methylation 
MGMT 
methylation 
RASSF1A 
methylation 
APC 
methylation 
IGF2 
methylation 
MLH1 
methylation 
Variables n Median P Median P Median P Median P Median P Median P 
Sex 
Female 32 145.921 
0.781 
54.394 
0.049 
0.000 
0.199 
20.028 
0.443 
75.824 
0.510 
2.248 
0.010 
Male 72 107.688 21.499 0.000 14.251 65.966 0.000 
Age Group 
18-56 34 118.231 
0.451 
20.158 
0.452 
0.000 
0.270 
17.542 
0.235 
86.093 
0.059 
0.936 
0.680 57-65 41 145.092 26.239 0.000 22.341 67.232 0.864 
66-85 29 93.747 31.629 0.000 9.535 54.145 0.803 
Mucinous 
histology 
No 100 127.550 
0.288 
27.133 
0.112 
  
0.296 
15.591 
0.125 
67.232 
0.296 
0.803 
0.275 
Yes 4 79.959 8.128 0.000 7.774 77.095 17.957 
Stage 
I and II 28 94.972 
0.001 
33.702 
0.183 
0.000 
0.646 
15.214 
0.716 
68.874 
0.513 
1.702 
0.535 III 32 53.125 24.307 0.000 14.948 72.671 1.814 
IV 44 179.276 28.626 0.000 15.591 61.247 0.000 
Primary Tumor 
(pT) 
T1 and T2 16 95.599 
0.820 
32.041 
0.714 
0.000 
0.362 
14.832 
0.525 
86.018 
0.668 
1.260 
0.462 
T3 84 123.484 24.412 0.000 14.989 64.811 0.000 
T4 4 267.495 105.671 0.269 26.666 71.659 5.188 
Tx 0 - - - - - - 
Regional Lymph 
Nodes (pN) 
N0 38 119.159 
0.788 
52.717 
0.266 
0.000 
0.597 
19.050 
0.969 
65.388 
0.913 
0.958 
0.758 
N1 32 131.317 17.908 0.000 15.591 68.364 0.000 
N2 30 120.858 24.879 0.000 14.238 69.570 1.396 
Nx 4 303.043 20.790 - 9.156 66.709 2.269 
Distant 
Metastasis (M) 
M0 60 75.598 
0.000 
25.264 
0.151 
0.000 
0.766 
15.214 
0.633 
70.148 
0.270 
1.704 
0.554 
M1 37 200.538 28.980 0.000 16.689 62.746 0.000 
M2 7 123.484 23.647 0.000 10.794 24.786 0.000 
Mx 0 - - - - -   
Neoadjuvant 
Treatment 
No 51 163.200 
0.002 
31.629 
0.012 
0.000 
0.802 
14.989 
0.403 
65.966 
0.974 
0.980 
0.547 
Yes 53 91.597 16.099 0.000 15.514 68.020 0.402 
KRAS Mutation: 
resistence 
NA 66 131.317 
0.242 
22.986 
0.110 
0.000 
0.552 
15.438 
0.949 
66.186 
0.656 
0.980 
0.614 
Yes 37 101.752 49.714 0.000 14.989 69.779 0.000 
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Appendix 4: Results II 
Table 24 – Cox regression assessing the potential of methylation in prediction of Disease-free survival (DFS) and 
disease-specific survival (DSS). * Non-hypomethylated used as indicator, all the other genes had non-
hypermethylated as indicator, n=214. 
Univariable analysis DFS DSS 
Gene Methylation HR (95% CI) P HR (95% CI) P 
SEPT9 Hyper 0.651 (0416-1.019) 0.060 0.721 (0.516-1.006) 0.054 
MGMT Hyper 0.709 (0.424-1.185) 0.189 0.915 (0.656-1.274) 0.598 
RASSF1A Hyper 0.884 (0.575-1.358) 0.573 1.011 (0.727-1.407) 0.946 
IGF2 Hypo* 0.968 (0.592-1.586) 0.899 0.928 (0.655-1.314) 0.673 
APC Hyper 0.943 (0.593-1.500) 0.805 0.835 (0.592-1.179) 0.306 
MLH1 Hyper 0.669 (0.434-1.033) 0.070 0.665 (0.476-0.930) 0.017 
 
 
Table 25 – Cox regression assessing the potential of clinical features in prediction of Disease-free survival (DFS) 
and disease-specific survival (DSS), n=214. 
Univariable analysis DFS DSS 
 n HR (95% CI) P HR (95% CI) P 
Stage 
I and II 52 1 (referent) 0.304 1 (referent) 0.000 
III 51 1.392 (0.896-2.162) 0.141 0.990 (0.651-1.506) 0.962 
IV 108 1.027 (0.591-1.785) 0.925 1.900 (1.323-2.728) 0.001 
Primary 
Tumor (pT) 
T1 and T2 22 1 (referent) 0.013 1 (referent) 0.000 
T3 172 1.437 (0.798-2.587) 0.227 1.050 (0.664-1.661) 0.835 
T4a and 
T4b 
17 5.826 (1.800-18.860) 0.003 3.288 (1.711-6.319) 0.000 
Regional 
Lymph 
Nodes (pN) 
N0 77 1 (referent) 0.261 1 (referent) 0.040 
N1 a, b, c 64 1.066 (0.673-1.688) 0.785 1.012 (0.703-1.457) 0.948 
N2 a,b 66 1.668 (0.989-2.813) 0.055 1.559 (1.100-2.209) 0.013 
Distant 
Metastasis 
(M) 
M0 103 1 (referent) 0.898 1 (referent) 0.000 
M1a 88 1.129 (0.675-1.889) 0.645 1.884 (1.382-2.568) 0.000 
M1b 20 - - 2.049 (1.224-3.431) 0.006 
Gender 
Male 139 1 (referent) - 1 (referent) - 
Female 74 0.686 (0.455-1.034) 0.072 1.023 (0.755-1.387) 0.883 
Neoadjuvant 
Treatment 
No 145 1 (referent) - 1 (referent) - 
Yes 68 1.224 (0.797-1.881) 0.356 1.365 (1.007-1.851) 0.045 
Age group 
18-57 76 1 (referent) 0.080 1 (referent) 0.001 
58-65 73 1.709 (1.064-2.746) 0.027 1.635 (1.146-2.332) 0.007 
66-85 64 1.179 (0.717-1.938) 0.517 1.994 (1.377-2.888) 0.000 
Colon 
Rectum 103 1 (referent) 0.085 1 (referent) 0.161 
Distal 73 0.647 (0.408-1.024) 0.063 0.979 (0.705-1.360) 0.901 
Proximal 37 1.183 (0.685-2.042) 0.547 1.429 (0.961-2.125) 0.078 
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Table 26 – Cox regression assessing the potential of methylation in prediction of disease-free survival (DFS) both 
in colon and rectum tumors. * Non-hypomethylated used as indicator, all the other genes had non-
hypermethylated as indicator, n=110 for colon and n=104 for rectum. 
Univariable analysis Colon Rectum 
Gene Methylation HR (95% CI) P HR (95% CI) P 
SEPT9 Hyper 0.600 (0.317-1.137) 0.117 0.653 (0.328-1.301) 0.225 
MGMT Hyper 0.748 (0.366-1.529) 0.426 0.647 (0.303-1.381) 0.260 
RASSF1A Hyper 1.016 (0.553-1.863) 0.960 0.683 (0.365-1.276) 0.232 
IGF2 Hypo* 1.043 (0.515-2.112) 0.908 0.939 (0.467-1.885) 0.858 
APC Hyper 0.854 (0.441-1.655) 0.640 1.126 (0.574-2.208) 0.730 
MLH1 Hyper 0.685 (0.368-1.276) 0.233 0.608 (0.328-1.129) 0.115 
 
Table 27 – Cox regression assessing the potential of clinical features in prediction of disease-free survival (DFS) 
both in colon and rectum tumors, n=110 for colon and n=104 for rectum. 
Univariable analysis 
Colon Rectum 
n HR (95% CI) P n HR (95% CI) P 
Stage 
I and II  24 1 (referent) 0.334 28 1 (referent) 0.939 
III 20 1.670 (0.847-3.293) 0.139 32 1.078 (0.598-1.943) 0.802 
IV 64 1.193 (0.572-2.486) 0.638 44 0.939 (0.397-2.222) 0.887 
Primary 
Tumor (pT) 
T1 and 
T2 
6 1 (referent) 0.025 16 1 (referent) 0.223 
T3 89 2.124 (0.829-5.444) 0.117 84 0.868 (0.397-1.896) 0.722 
T4a and 
T4b 
13 11.44(1.947-67.229) 0.007 4 3.201 (0.638-16.066) 0.158 
Regional 
Lymph 
Nodes (pN) 
N0 39 1 (referent) 0.344 38 1 (referent) 0.579 
N1 a, b, 
c 
33 1.194 (0.606-2.356) 0.608 32 0.898 (0.475-1.698) 0.740 
N2 a,b 36 1.751 (0.825-3.715) 0.144 30 1.513 (0.725-3.155) 0.270 
Distant 
Metastasis 
(M) 
M0 44 1 (referent) 0.565 60 1 (referent) 0.802 
M1a 51 1.456 (0.730-2.904) 0.286 37 0.903 (0.405-2.010) 0.802 
M1b 13 - - 7 - - 
Gender 
Male 68 1 (referent) - 72 1 (referent) - 
Female 42 1.085 (0.603-1.954) 0.785 32 0.296 (0.149-0.589) 0.001 
Neoadjuvant 
Treatment 
No 94 1 (referent) -  51 1 (referent) -  
Yes 16 1.633 (0.580-4.601) 0.353 53 1.030 (0.596-1.778) 0.916 
Age group 
18-57 38 1 (referent) 0.311 39 1 (referent) 0.343 
58-65 37 1.718 (0.842-3.503) 0.137 36 1.601 (0.848-3.021) 0.147 
66-85 35 1.151 (0.566-2.340) 0.697 29 1.172 (0.574-2.392) 0.664 
Colon 
Proximal 37 1 (referent) 0.062 - - -  
Distal 73 0.563 (0.307-1.030) 0.062 - - - 
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Table 28 – Cox regression assessing the potential of methylation in prediction of disease-specific survival (DSS) 
both in colon and rectum tumors. * Non-hypomethylated used as indicator, all the other genes had non-
hypermethylated as indicator, n=110 for colon and n=104 for rectum. 
Univariable analysis Colon Rectum 
Gene Methylation HR (95% CI) P HR (95% CI) P 
SEPT9 Hyper 0.624 (0.394-0.988) 0.044 0.805 (0.492-1.316) 0.386 
MGMT Hyper 0.871 (0.543-1.398) 0.568 0.976 (0.611-1.556) 0.917 
RASSF1A Hyper 0.861 (0.546-1.357) 0.518 1.170 (0.722-1.896) 0.524 
IGF2 Hypo* 1.115 (0.683-1.821) 0.663 0.778 (0.473-1.279) 0.322 
APC Hyper 0.704 (0.436-1.138) 0.152 0.992 (0.602-1.632) 0.973 
MLH1 Hyper 0.563 (0.352-0.898) 0.016 0.787 (0.485-1.279) 0.334 
 
Table 29 – Cox regression assessing the potential of clinical features in prediction of disease-specific survival 
(DSS) both in colon and rectum tumors, n=110 for colon and n=104 for rectum. 
Univariable analysis 
Colon Rectum 
n HR (95% CI) P n HR (95% CI) P 
Stage 
I and II  24 1 (referent) 0.008 28 1 (referent) 0.005 
III 20 0.800 (0.411-1.556) 0.511 32 1.171 (0.670-2.046) 0.579 
IV 64 1.758 (1.060-2.917) 0.029 44 2.208 (1.289-3.784) 0.004 
Primary 
Tumor (pT) 
T1 and 
T2 
6 1 (referent) 0.000 16 1 (referent) 0.201 
T3 89 1.814 (0.727-4.526) 0.201 84 0.790 (0.457-1.364) 0.397 
T4a and 
T4b 
13 6.858 (2.336-20.128) 0.000 4 1.880 (0.623-5.673) 0.262 
Regional 
Lymph 
Nodes (pN) 
N0 39 1 (referent) 0.287 38 1 (referent) 0.125 
N1 a, b, 
c 
33 1.043 (0.623-1.749) 0.872 32 1.045 (0.621-1.759) 0.868 
N2 a,b 36 1.557 (0.957-2.534) 0.075 30 1.612 (0.972-2.674) 0.064 
Distant 
Metastasis 
(M) 
M0 44 1 (referent) 0.024 60 1 (referent) 0.003 
M1a 51 1.957 (1.252-3.060) 0.003 37 1.923 (1.226-3.017) 0.004 
M1b 13 1.876 (0.966-3.643) 0.063 7 2.967 (1.241-7.092) 0.014 
Gender 
Male 68 1 (referent)  - 72 1 (referent) -  
Female 42 1.019 (0.667-1.557) 0.931 32 0.980 (0.633-1.519) 0.929 
Neoadjuvant 
Treatment 
No 94 1 (referent)  - 51 1 (referent)  - 
Yes 16 2.065 (1.193-3.576) 0.010 53 1.307 (0.865-1.975) 0.203 
Age group 
18-57 38 1 (referent) 0.021 39 1 (referent) 0.056 
58-65 37 1.696 (1.007-2.856) 0.047 36 1.545 (0.946-2.524) 0.082 
66-85 35 2.061 (1.224-3.469) 0.007 29 1.866 (1.096-3.177) 0.022 
Colon 
Proximal 37 1 (referent)  - - - - 
Distal 73 0.666 (0.434-1.023) 0.064 - - - 
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